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Abstract 
The main aim of this study was to investigate effects of the perfluorinated compounds 
perfluorooctanesulphonate (PFOS) and perflouorononanoic acid (PFNA) using the human 
adrenocortical carcinoma cell line – H295R. Perfluorinated compounds (PFCs) are stable 
chemicals used widely in products such as paint and stain repellants. These compounds 
are known to be able to act as endocrine disruptors. H295R is a well-known and a much 
used model because among other reasons of its ability to produce hormones related to the 
stereoidogenesis.  
In this study the H295R cells were exposed in 48h to three different concentrations, 150 
µM, 175 µM and 200 µM, of PFOS and PFNA in 75cm2 tissue culture flasks. The 
viability was measured with the alamarBlue ® assay, while four hormones related to the 
steroidogenesis, oestradiol, testosterone, cortisol and progesterone, were measured by 
using radioimmunoassay. RNA, DNA and proteins were isolated from the exposed cells, 
and toxic effects on the cell-model were investigated by using proteomics. 2D gels were 
performed to separate the proteins, and statistically significant proteins spots were excised 
and identified by LC-MS/MS followed by on-line database searches, using SwissProt and 
NCBInr databases. Western blot was used to quantitatively validate the findings. In 
addition, other proteins were chosen for western blot in the light of knowledge of proteins 
involved in steroidogenesis and cellular stress.  
Exposure to PFOS had a cytotoxic effect on the cells at all three concentrations. In 
addition, exposure to PFOS caused an increased oestradiol at the lowest concentration, 
but no significant alterations at the two highest concentrations. Testosterone secretion was 
decreased at the highest concentration, and cortisol and progesterone secretion was 
decreased at all concentrations. Exposure to PFNA caused a statistically non-significant 
increased secretion of oestradiol and a statistically significant decreased secretion of 
testosterone, cortisol and progesterone at all concentrations. Seventeen of the protein 
spots that showed significant differences in normalized volumes were identified and 
included proteins involved in transcription/protein synthesis, transport, and stress 
response. The western blots showed increased vimentin in cells exposed to PFNA, and 
decreased levels of BAX were found in cells exposed to PFOS.  
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In conclusion, exposure to PFOS and PFNA were found to alter adrenal steroidogenesis 
and protein expression in the H295R in vitro model. Although the mechanisms of these 
alterations are not known, the current study might contribute in a better understanding of 
effects of PFOS and PFNA. The alterations in protein regulation suggested that exposure 
to these compounds affects several cellular processes, including protein synthesis, stress 
response and apoptosis. In addition, many of the altered proteins have been reported to be 
involved in carcinogenesis.  
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1. Introduction 
1.1 Worldwide exposure to persistent organic pollutants (POPs) 
Persistent organic pollutants (POPs) are a group of chemicals which have recently 
become a great concern in the environment. They are carbon-based and are primarily 
products and by-products of industrial processes. Among the most well-studied 
compounds are polychlorobiphenyls (PCBs), dioxins such as tetrachlorobenzo-p-dioxin 
(TCDD) and organochlorine pesticides such as dichloro-diphenyl-trichloroethane (DDT) 
(Corsolini et al. 2005). Most of the POPs resist photolytic, biological and chemical 
degradation, and some of the substances are semivolatile (Fisher 1999). The POPs have 
been used for several years, and occurrence of these substances in humans and in the 
environment have been reported since the early 1960s (Li et al. 2006). Due to their 
resistance of degradation, the POPs bioaccumulate in the environment, and are able to be 
transported far distances from the point-sources. The POPs are often made volatile in 
tropic areas with relatively high temperature and are transported and deposited worldwide 
(Li et al. 2006). This way of transportation is called the “grasshopper effect”, and the 
process is often seasonal. The substances are released into the environment as for 
example vapor, and are deposited another place in the world through for example a 
rainfall (Fisher 1999). POPs have been found in organisms in the Arctic regions where 
there are few sources of contaminations, as well as in heavily populated, industrial areas.  
A common problem occurring when the POPs are tried to be replaced in industrial 
purposes, is the developing countries’ disability to take the cost for the replacement. The 
alternative chemicals for POPs are often more expensive, and there has not been done 
enough research for the health effects for some of the replacing chemicals (Fisher 1999).  
Some of the toxic effects that have been associated to exposure to POPs are cancer, 
reproductive and developmental problems such as low birth weight, hormone alteration, 
lower IQ and emotional problems, alterations of the immune system, endocrine 
disruption, central nervous system defects, effects on the nervous system, liver damage, 
skin and eye disease, and death (Corsolini et al. 2005). 
Monitoring of humans has shown that POPs continue to be present in most food chains 
worldwide. Even if concentrations in the environment of some POPs have been reduced 
since the 1960s and 1970s, both human and animal exposure continues. The reductions in 
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discharge of toxic substances are not necessarily reflected in measured concentrations in 
animal and human populations due to many POPs ability to increase with the age of the 
exposed organism. So even if the exposure decreases, the average concentration in a 
population will stay the same (Porta et al. 2008).  
Most POPs are stored in fatty tissue, due to their lipophilic properties. Nearly all humans 
have POPs in various concentrations in their livers and other fatty tissues. Although many 
of the POPs have been restricted or banned, levels of these POPs can still be found in the 
environment. The most common source of contaminants for human exposure is via the 
diet, specially via fat fish and fatty tissues from animals (Porta et al. 2008).  
The potential of a substance to bioaccumulate in an organism is expressed either as the 
bioaccumulation factor (BAF), the bioconcentration factor (BCF), or by using the 
octanol-water coefficient (KOW). BAF and BCF are calculated by measuring the total 
concentration in an organism and compare this to the surrounding medium. The KOW is a 
value for how much of a substance that solves in water compared to octanol. If a 
substance is more soluble in octanol, this means that it is more lipophilic and have the 
potential to accumulate in lipids (Li et al. 2006).  
 
1.2 Perfluorinated compounds (PFCs) – History and utilization 
Perfluorinated compounds (PFCs) are man-made chemicals, and are rarely found 
naturally. They have been used since the 1950s due to their unique physic-chemical 
properties such as chemical and thermal stability, low surface free energy and surface 
active properties (Fromme et al. 2009). In addition the PFCs are both fat and water 
repelling, due to their structure, and are typically used as surfactants in non-stick 
products, stain-resistant fabrics and all-weather clothing (Skoog et al. 2008). The PFCs 
have also been used in food packaging and flame retardant foams (Bjork et al. 2008) as 
well as in electronic and photographic devices, cosmetics, and surfactants in various 
cleaning agents (Fromme et al. 2009). 
PFOS and PFOA are the two most well-known and most studied PFCs found both in the 
environment and in humans. PFOS is found to be most abundant (Jensen et al. 2008). 
 
16 
    
The Organisation for Economic Co-operation and Development (OECD) had several 
meetings from 2000 to discuss the rising concern about the hazards of PFOS and its salts. 
The Chemical Committee and the Working Party on Chemicals, Pesticides and 
Biotechnology made an assessment, and this document was published in 2002 
(ENV/JM/RD(2002)17/FINAL 2002). In the same time period, the major manufacturer, 
3M, decided to phase out the production of PFOS and PFOS-related substances due to the 
findings of PFOS dispersed in the environment, including in humans (3M 2000). The 
phase out of production of PFOS was decided in May 2000 and was completed in 2002.  
In 2001 an international treaty was signed to control the release of POPs into the 
environment. This treaty is called the Stockholm Convention on Persistent Organic 
Pollutans. This treaty originally listed twelve chemicals of concern; “the Dirty Dozen”. 
These chemicals are monitored internationally to be eliminated, to restrict the use and/or 
to reduce release into the environment. The Stockholm Convention decided in Geneva in 
May 2009, to include PFOS and its salts in addition to “the Dirty Dozen” (Wang et al. 
2009). 
The production of PFOS and PFOS-related product has decreased, but due to specialized 
industrial processes with no possible replacements, PFOS is still being produced in some 
countries. The regulations are very different in countries worldwide when it comes to 
releasing POPs into the environment, so countries with less stricter regulations have taken 
over the production from industrial countries with stricter regulations including the U.S. 
(Wang et al. 2009). 
In 2005 the environmental authority in Norway worked out a plan of action for 
perfluorinated compounds. This included initiatives to reduce the discharge of PFOS and 
plans to increase the health- and environmental knowledge when it comes to the 
properties of other perfluorinated compounds. A prohibition against the use of PFOS and 
PFOS-related compounds in firefoam, textiles and impregnating agents were introduced 
in Norway in April 2007. In 2008 The Norwegian Pollution Control Authority (KLIF)  
published a revised plan of action for the work with reducing the perfluorinated 
compounds (KLIF 2008). This plan has PFOS and perfluoroanoic acid (PFOA) as main 
focuses since these two compounds are mostly widespread. However, the plan aims at 
stopping or reducing the discharge of all PFOS- and PFOA like substances.  
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There is no production of perfluorinated compounds in Norway, and all the products 
containing these compounds are imported either as chemical-technical products or as 
component parts in processed products. The most known brands in Norway containing 
perfluorinated compounds are Gore Tex® and Teflon®. Both of these brands is 
manufactured from polytetrafluoroethylene (PFTE) and utilizes PFOA (Jensen et al. 
2008). 
Degradation of fluorotelomer alcohol (FTOH) is likely to be an important source of PFC 
pollution (Ellis et al. 2004). A study done by Tomy et al. (2004) showed levels of PFOS 
in livers of rainbow trout exposed to N-Ethyl perfluoroctanesulfonamid suggesting a 
possible biotransformation route. This may explain the detection of PFOS in fish despite 
the nonvolatile nature of PFOS (Tomy et al. 2004b).  
 
1.3 H295R – the adrenocortical carcinoma cell line 
The adrenocortical carcinoma cell line – H295R – was derived from a human adrenal 
carcinoma and has all the enzymes necessary for producing hormones. The cells maintain 
the ability of expressing all the genes needed for production of these enzymes. Thus the 
H295R cells have the capacity of producing all the hormones involved in the 
steroidogenesis (Gazdar et al. 1990).  
The H295R cell model has shown to help understanding modes of action for several 
substances, which can reduce the need for laboratory animals as well as being a fast and 
sensitive tool for screening chemicals (Gracia et al. 2006). In 2006 the first article where 
the cell model was used to look for endocrine disruption after exposure, in this case to 
contaminated sediment, was published. The researchers concluded that this model can be 
used as a model for endocrine disruption, but confirmations must be conducted in in vivo 
models – hence the H295R cells is a good tool for pre-screening (Bláha et al. 2006; 
Gracia et al. 2007). The model has been compared to fish models to see if it gives 
satisfactory results when compared with effects on whole organisms. The study showed 
variations, but the H295R cell model was more consistent and reproducible than the fish 
models (Villeneuve et al. 2007). The growing focus on reduce, replace and refine studies 
involving laboratory animals has contributed to make the H295R cell model useful on 
basal functions and regulation on human adrenocortical steroidogenesis (Oskarsson et al. 
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2006). In conclusion this cell-line has been frequently used, and today it is a standard 
model for study of human adrenocortical steroidogenesis (Nicol et al. 2009).  
In the current study, alterations of the steroidogenesis in the H295R cells were measured 
by quantifying four of the steroidogenic hormones; oestradiol, testosterone, progesterone 
and cortisol. These were chosen due to their importance in reproduction and development. 
 
1.4 Proteomics 
The human genome project has recently sequenced the whole human genome, and has 
provided information about most of the individual genes’ sequences. However, genomics 
do not give information about the dynamic cellular processes such as the post-
translational modifications of the proteins, which is important for protein function 
activity, or the amount of active proteins in a cell (Chambers et al. 2000). The genetic 
material is the basis for production of all cellular proteins. The information includes 
organization of genes and transcriptional regulatory elements on chromosomes, which 
contributes to understanding the gene functions and their role in specific processes 
(Heijne et al. 2005). Genomic analysis measures the mRNA levels which provide 
information on gene expression, but these levels do not necessarily correlate with protein 
abundance. The levels of mRNA and the corresponding protein may vary a great deal 
(Rohrbough et al. 2007). The lack of correlation may be caused by post-translational 
modifications, as already mentioned, such as phosphorylation, acetylation, glycosylation, 
ubiquitination etc. which may regulate the proteins. Another limitation of genomics is that 
one gene not necessarily codes for one protein. The proteins contain polymorphisms that 
may cause different functions. In addition many mRNAs are known to be differentially 
spliced, generating several proteins (Barrier et al. 2005). 
Proteomics however, gives the opportunity to identify post-transcriptional modifications 
and protein interactions in addition to identification of proteins. This contribute to give a 
better understanding of disease processes and mechanisms of action (Stigliano et al. 
2008) . Proteomics have been defined as the study of protein properties (expression level, 
post-translational modifications, interactions etc) on a large scale to be able to investigate 
the global, integrated view of disease processes, cellular processes and networks at a 
cellular level (Blackstock et al. 1999).  
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Proteomic analysis measures all the proteins of a cell at a given time. In comparison to 
the genome which is the same in all the cells, the proteome is different is each cell type in 
an organism. The proteome will change over time as the organism grows. In addition, 
infections, use of medication, diet, exercise etc will alter the proteome as response to 
fluctuations in the intracellular and extracellular environments (Campbell et al. 2003). 
Proteomics is considered more complex than genomics, due to the need of more 
information to interpret the results. There is need of information about functions of the 
proteins, their structure, their interactions, and which proteins are present at different life 
stages. In comparison, the genome is the same in all the cells and alterations caused by for 
example mutations are easier to discover (Campbell et al. 2003).  
A difficulty concerning protein analysis is to detect low abundance proteins compared to 
the more abundant ones. In addition the smaller proteins can be difficult to detect as 
larger proteins appear more clearly (Rohrbough et al. 2007). 
There are several ways of quantification and identification of proteins. The methods used 
in this study will be further described in the background chapter.  
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1.5 Aims of the study 
The aims of this study were to investigate effects of the perfluorinated compounds 
perfluorooctanesulphonate (PFOS) and perflouorononanoic acid (PFNA) on protein 
expression and endocrine function in the human adrenocortical carcinoma cell line – 
H295R.  
Specific aims: 
1. To investigate protein expression in response to PFOS and PFNA exposure in the 
adrenocortical carcinoma cell line H295R 
2. To investigate endocrine responses to PFOS and PFNA in the cell line H295R by 
measuring alterations in four of the hormones involved in steroidogenesis; 
oestradiol, testosterone, progesterone and cortisol  
3. To validate proteomic results after exposure to PFOS and PFNA in H295R cells 
using western blot 
4. To quantify proteins involved in steroidogenesis and cellular stress using western 
blot 
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2. Background 
2.1 Perfluorinated compounds (PFCs) 
2.1.1 Structure of PFCs 
The PFCs are built up of a chain of carbon that makes up the linear backbone of the 
molecule. The molecule consists of typically 4-14 carbon atoms, and the hydrogen atoms 
are replaced by fluorine atoms (Lau et al. 2007). Fluorine is one of the most reactive 
atoms in ionic form, and one of the most stable atoms in bound form (Lau et al. 2004). A 
functional group is attached to the backbone of carbon, and gives the compound its 
chemical properties. Due to the functional group, the perfluorinated compounds are both 
hydrophilic and hydrophobic; the perfluorinated alkyl chain is hydrophobic and the 
functional group is hydrophilic (Fang et al. 2010). The most abundant functional groups 
are sulfonate and carboxyl. Thus the two main groups of PFCs are perfluorinated 
sulfonates, including PFOS, and perfluorinated carboxylic acids, including PFNA 
(Haukås et al. 2007). 
The last years PFCs have emerged as a concern in the environment because of their 
stability and persistence in the environment (Lau et al. 2007). The stability is mostly 
caused by the replacement of all or some of the carbon-hydrogen bonds by carbon-
fluorine bonds (C-F bonds). The C-F bonds are very strong and are resistant to various 
degradations such as reactions with acids and bases, oxidation and reductions (Fromme et 
al. 2009) as well as resistance to hydrolysis, photolysis, microbial degradation and living 
cell metabolism (Kleszczynski et al. 2007). The fluorine is highly electronegative and will 
attract the electrons in a chemical bond toward itself. This gives the C-F-bonds polarity 
and strength. In addition, fluorine has three pairs of electrons not involved in binding to 
other atoms which gives highly fluorinated systems high thermal and chemical stability 
(Giesy et al. 2002). Naturally occurring PFCs are rare due to the requirement of high 
energy to break or form the C-F bonds (Lau et al. 2004). Naturally occurring PFCs 
usually contain one fluorine atom and are referred to as fluorinated organic compounds 
(FOCs), while the synthetic PFCs often contain several fluorine atoms and might also be 
fully fluorinated (Giesy et al. 2002). Due to these C-F bonds, PFCs have been considered 
to be metabolically inert and non-toxic (Hu et al. 2005). 
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A study done in rats concluded that PFCs with longer carbon chain length have greater 
potential to accumulate in the liver. In addition longer perfluoralkyl chains are likely to be 
more potent to peroxisomal β-oxidation (Kudo et al. 2006). The length of the carbon 
chain has also proven to affect the elimination rate of perfluorinated fatty acids. Longer 
carbon chains give slower elimination through urine. Thus PFNA has a slower 
elimination rate than PFOA (Kudo et al. 2001).  
Field-based and laboratory-based studies reported that BMFs and BAFs increase with 
increasing perfluoralkylated chain (Houde et al. 2006). 
PFCs have been reported to have various effects in several organisms due to their 
structure. Perfluorinated fatty acids have structural similarity to natural endogenous fatty 
acids. The combination of this and surface acting physio-chemical properties and 
membrane-related effects, the PFCs have attracted interest  in studies of effects of 
permeability status of the cell membrane (Hu et al. 2003).  
Previous studies have suggested that perfluorinated compounds have an effect on gap 
junction intercellular communication, and some of the effect may be due to alterations of 
membrane fluidity. The membrane fluidity affects movement of molecules in the 
membrane, and thereby affects lipid-lipid, lipid-protein and protein-protein interactions. 
Alterations of the membrane fluidity caused by xenobiotic compounds may have effects 
on the functions of the membrane and its associated substructures (Hu et al. 2003).  
PFC’s are peroxisome proliferating compounds, and are found to be agonists to the 
peroxisome proliferator-activating receptors (PPAR). This may affect anti-inflammatory 
and immunomodulatory actions such as nuclear factor-kappa B (NF-KB) signaling 
pathway. This pathway is a DNA binding-independent interference of transcription 
factors (Fang et al. 2008).  
The perfluorinated compounds has shown to give developmental neurotoxic effects in 
vivo in the form of a direct action on replicating and differentiate neurons (Slotkin et al. 
2008).  
PFCs have been found to have three basic effects of mitochondrial bioenergetics; 
nonspecific increase in ion permeability of the mitochondrial membrane, ionizable 
amides may cause a specific and potent uncoupling of mitochondrial oxidative 
phosphorylation, and interference of mitochondrial bioenergetics by inducing 
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mitochondrial permeability transition, leading to inhabitation of ATP synthesis and 
release of apoptogenic factors (Starkov et al. 2002). 
Certain fluorotelomere alcohols are suggested to induce hepatic vitellogenin mRNA and 
protein via estrogen receptor signaling in male medaka. In mammals some of the 
fluorotelomere alcohols are metabolized to PFOA and PFNA, which induce peroxisomal 
proliferation (Ishibashi et al. 2008). 
 
2.1.2 Perfluorooctane sulfonate (PFOS) 
Perfluorooctane sulfonate (PFOS) is a perfluorinated compound which contains an eight-
carbon backbone as shown in Fig 2.1. It appears to be the final degradation product of 
many of the commercially produced PFCs (Krøvel et al. 2008).   
PFOS does not decompose in nature, and PFOS related compounds have proved to up-
concentrate in the food chain. Studies have shown that PFOS is toxic to repeated 
exposures, has reproductive effects on mammals and might be carcinogenic (TA-
2395/2008, (KLIF 2008). 
PFOS is primarily absorbed and distributed in the serum and the liver, but poorly 
eliminated (Lau et al. 2004). The substance binds to proteins rather than to fatty lipids as 
opposed to many other POPs (Wang et al. 2009). 
PFOS has shown to give diverse effects in laboratory animals including decreased body 
weight, enlarged liver, hepatotoxicity, decreased serum cholesterol levels, teratogenicity, 
neurotoxicity, induced peroxisome proliferation and endocrine disruption. However, most 
of the effects on laboratory animal occur after exposure to higher concentrations than 
found in the environment (Wang et al. 2009).  
Exposure of PFOS has demonstrated both maternal and developmental toxicity in rat and 
mouse. The maternal toxicity includes deficits in weight gain during pregnancy and 
increased liver weight (Thibodeaux et al. 2003). In subchronic toxicity tests of PFOS in 
cynomolgus monkeys, the effects included decreased body weight, increased liver weight, 
lowered serum total cholesterol concentrations, lowered triiodothyronine concentrations 
and lowered estradiol levels (Seacat et al. 2002). 
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In various species of fish, PFOS has shown capability of inducing oxidative stress. This 
suggests that some of the toxicity of PFOS might be associated with reactive oxygen 
species (ROS) (Oakes et al. 2005).  
In a study done by Hu et al. (2003), PFOS was reported to increase the membrane 
permeability of cells to two model compounds, TCDD and E2. The amount of the two 
ligands reaching the cell signaling pathways were increased while PFOS itself were 
inactive. In addition PFOS was able to decrease mitochondrial membrane potential in 
exposed cells (Hu et al. 2003). 
There is found high levels of PFOS related compounds in the blood of exposed workers 
in USA. Also relative low levels of PFOS related compounds are found in the regular 
population several places in the world (TA-2395/2008, (KLIF 2008).  
 
 
Figure 2.1: An illustration of the structure of perfluorooctane sulfonate. 
 
2.1.3 Perfluorononanoic acid (PFNA) 
Perfluorononanoic acid (PFNA) contains a nine-carbon backbone as shown in Fig 2.2, 
and is the third most abundant PFC in the environment. PFNA can be bioaccumulated and 
biomagnified through food webs, and in animal experiments it has shown potential 
reproductive interferences. PFNA has been found throughout wildlife species such as 
amphipods, fish, birds and mammals including humans. The source of PFNA is not 
known, but a likely source is atmospheric FTOH emitted through industrial activities 
which produces perfluorinated carboxylic acids upon degradation (Fang et al. 2008).  
PFNA is different from PFOS and PFOA due to the nine perfluorinated carbonatoms in 
the chain of alkyls, instead of eight. This is likely to make PFNA more toxic than the 
other two compounds (Fang et al. 2009). 
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Due to the increasing knowledge of PFOS’ toxicity, some fluoropolymer industries use 
PFNA instead of PFOS and PFOA in the manufacturing of fluoropolymers such as 
polyvinylidene. A consequence of this is the finding of high concentrations of PFNA in 
organisms (Fang et al. 2010). Another reason is that the longer-chain PFAAs showed 
more bioaccumulation than other shorter homologues (Alexander et al. 2007). 
PFNA has shown to promote apoptosis in rat spleens. The mechanism behind this may be 
the activating of PPARs which leads to increased peroxisomal β-oxidation and the 
production of excess H2O2. Decreased activity of superoxide dismutase has also been 
found, and contributes to the damage caused by oxygen species. In addition increased 
levels of cytokines have been found in the rat spleen, suggesting an increased apoptosis 
(Fang et al. 2010).  
There are no reports about adverse clinical effects from occupational exposure to PFNA 
(Mundt et al. 2007). 
 
 
Figure 2.2: Illustration of the structure of perfluorononanoic acid (PFNA) 
 
2.1.4 Exposure in the environment and wildlife 
Although PFCs have been used since the 1950s, it has been difficult to investigate the 
effects in the environment due to lack of measurement techniques. Due to the PFCs 
surface-active properties, the compounds are more difficult to separate from tissues than 
other POPs. In addition the compounds demand specialized liquid chromatography/mass 
spectrometry methods for analysis (Giesy et al. 2001).   
PFOS act differently from other POPs when it is released into the environment, including 
intrinsic properties such as surface activity, water solubility, non-measurable KOW values, 
and relatively low bioaccumulation potential (Wang et al. 2009). 
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PFC’s have been found in several matrixes, for example surface waters, air, sludge, soils, 
sediments and ice caps. However water is expected to be the most common compartment 
where PFC’s are found due to their physical-chemical properties. PFC’s found in other 
matrixes are more likely to be associated to the water phase of the compartment and there 
may be weak electrostatic interactions (Lau et al. 2007).  
The dispersion of PFC’s is not certain, but there are two theories; long range transport by 
oceanic currents or atmospheric transport and transformation of precursor chemicals. 
Anyhow, PFC’s are found in less populated areas as well as urban areas (Lau et al. 2007). 
In 2001, Giesy and Kannan reported for the first time about the dispersion of PFOS. This 
report was part of a bigger study were the distribution and effects of PFOS were 
investigated in tissues from various species, including fish, birds and marine mammals. 
The tissues were collected from many parts of the world, including urbanized areas in 
North America, the Arctic and the Baltic Sea, amongst others. The results confirmed that 
PFOS is widely distributed at a global level, can be persistent and bioaccumulate in food 
chains (Giesy et al. 2001). The same year PFOS was detected in blood and livers from 
marine mammals, including dolphin, ringed seal and cetaceans collected from various 
areas in the world. Interestingly the study showed that PFOS did not seem to increase 
with the age of the marine animals (Kannan et al. 2001). Another study confirmed this by 
looking at levels of PFOS in livers from birds. The result was no correlation between 
PFOS concentrations and sex or age of the birds. One reason suggested was that due to 
PFOS’ affinity for binding to proteins in plasma and liver, the accumulation is controlled 
by a dynamic equilibrium between uptake and elimination or related protein turnover. In 
comparison, other POPs accumulate in fatty tissue and are transmitted throughout the 
food chains (Kannan et al. 2002a). Concentrations of PFOS and related compounds 
measured in mink in the United States also confirmed no correlation between 
concentration of PFOS and sex or age. Locations and concentrations of PFOS were 
compared, and mink living in more urbanized areas with or without industry had greater 
concentrations of PFOS and its related compounds (Kannan et al. 2002b). 
Although there are variations, mammals feeding at higher trophic levels in the food web 
have higher concentrations of PFCs than the mammals feeding at lower trophic levels. 
This has been stated in several studies (Giesy et al. 2001; Martin et al. 2004; Tomy et al. 
2004a). In marine environment of Greenland and the Faroe Island PFCs, particularly 
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PFOS, were found to be important contaminants. Concentrations of PFOS were found to 
follow biomagnification along the food chain, with highest concentrations found in livers 
from polar bears (Bossi et al. 2005). Occurrence of PFOS in the Great Lakes in the United 
States was found in all trophic levels of the food chain, with a tendency of 
biomagnification at higher trophic levels. Due to the better ability of organisms at higher 
trophic levels of metabolizing the precursor compounds of PFOS, levels of un-
metabolized precursors of PFOS in organisms at lower trophic levels serve as a 
contributory source of PFOS for the organisms at higher trophic levels of the food chain 
(Kannan et al. 2005). There was not found any biomagnification in aquatic organisms of 
the food web investigated in the Canadian Arctic (Kelly et al. 2009).   
The effect on sediment-dwelling organisms have not been marked, but the organisms 
might be affected by chronic exposure (Stomperudhaugen et al. 2009).   
PFOS has been found to be acute toxic for fish both in saltwater and freshwater in short-
term exposure studies. This apply to water-living invertebrates as well (Yamashita et al. 
2005). 
 
2.1.5 Exposure in humans 
Occurrence of PFCs have been investigated in human tissues since the late 1960s, but it is 
not until lately when specific analysis of each compound have been developed, the serum 
of employers in fluorochemical manufacturing industry have been analyzed for PFCs 
(Kannan et al. 2004).  
Since PFCs have most affinity for binding to proteins, the compounds mainly accumulate 
in organs such as liver, kidney and spleen, but also in testicles and brain. The half-life is 
different for the various compounds, but are relatively very long for all of them (Jensen et 
al. 2008). PFCs have a high affinity for binding to albumin in the plasma, and this affinity 
may be caused by their structure. Interactions between proteins and surfactants are 
stronger when the compound contains fluorine atoms, which makes the compound more 
hydrophobic. In addition compounds with longer hydrophobic chains have stronger 
ability to bind to proteins such as albumin (Li et al. 2009). In addition, the ratios of PFOS 
between whole blood, serum and plasma have been measured. This showed that the ratio 
between plasma and serum is 1:1, while the ratio between serum/plasma and whole blood 
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is 2:1 independent of the levels measured for PFOS. This indicates that serum and plasma 
is the preferable matrix for PFOS (Ehresman et al. 2007). Elimination of PFCs by the 
kidneys are poor due to the plasma protein bindings (Harada et al. 2005). 
The main source of exposure in humans is assumed to be dietary intake (Fromme et al. 
2009). Still, an association between serum levels of PFCs and measured concentrations in 
the food has not yet been proved. This indicate that dietary intake is not the only source of 
exposure in humans (Kärrman et al. 2009). Ingestion or inhalation of dust released from 
treated or contaminated products containing PFOS might be an additional major intake 
source (Fisher 1999). In addition migration from food-packaging, such as microwave 
popcorn bags, through metabolism of fluorotelomer-based precursors can be an indirect 
source for humans (Houde et al. 2006). However migration from cookware has found to 
be relatively low (Begley et al. 2005). 
A study done by Kannan et al. (Kannan et al. 2004) investigated human blood samples 
from different countries, both industrial and developmental, to see the distribution of the 
PFCs around the world. The study showed that there were variations between the 
countries, but PFOS in various amounts was found in serum from all the countries 
investigated. The same study showed a lack of both gender- and age-dependent 
accumulation patterns. This may be related to the perfluorinated compounds affinity for 
lipoproteins rather than neutral lipids. However serum samples from fluorochemical 
production employees show no substantial changes in serum hepatic enzymes, cholesterol 
or lipoproteins associated with PFOS concentrations (Olsen et al. 1999).  
A study done on blood-samples from Nunavik Inuit adults in Canada showed that 
consumption of fish and marine mammals, male gender and age were the strongest 
predictors of PFOS plasma concentrations. The age-dependency suggests that PFOS has 
bioaccumulative properties like other POPs including PCBs and other organochlorines 
(Dallaire et al. 2009). The gender differences have been found in several studies, but the 
faster elimination by females is not consistent. The half-life of PFOA is shorter in male 
hamsters and cynomolgus monkeys, while it is faster in female rats and there is no 
difference in mice or rabbits (Lau et al. 2007). It appears that humans have a long half-life 
of serum elimination of PFOS and PFOA (Olsen et al. 2007).  
There have not been many studies investigating the extent of infant exposure of PFCs 
through breast milk. One pilot study found relative low exposure through breast milk, and 
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the concentration of PFCs were found to be much lower in the breast milk than in serum. 
This might be due to the PFCs affinity for proteins which inhibit the transfer to the human 
milk. This study suggested that further studies must be done to get more certain results 
(Ehrenstein et al. 2009). Another study indicated the same. PFCs were measured in 
human liver and milk, where several PFCs including PFOS, PFOA and PFNA were 
detected in the liver samples and in the serum, while the levels were lower in the milk 
samples compared to the liver samples (Kärrman et al. 2010). 
Several studies indicate that PFOS may be able to cross the placenta barrier, and thus 
enter the fetus’ circulation after maternal exposure. A study done by Inoue et al. indicates 
that there might be a barrier effect and that PFOS does not completely pass into the fetal 
circulation (Inoue et al. 2004). 
Apelberg et al. (2007) found small negative associations between PFOS concentrations 
and birth weight and size in humans, measured in cord serum taken from cord blood 
(Apelberg et al. 2007). 
Neonatal exposure of PFOS in mice has shown to affect proteins important for normal 
brain development. If the exposure happens during a critical step of the brain growth, 
alterations in these proteins might be one of the mechanisms behind behavioral defects 
(Johansson et al. 2009). 
In serum samples from the Norwegian population, the time trend shows an increased level 
of eight PFCs, including PFOS and PFOA, from the 1970s followed by a decline in PFOS 
and PFOA from the 2000s. This suggests that the use of PFCs has been reduced after 
various reports published around this time period (Haug et al. 2009). 
 
2.2 The human adrenal gland 
The adrenal gland is an endocrine organ important in both synthesis of steroid hormones 
and as part of the sympathetic nervous system. The gland is composed of two distinct 
endocrine components; the cortex and the medulla. The adrenal medulla synthesizes and 
secretes the vasoactive amines, adrenalin and noradrenalin (Stevens et al. 2000).  
The adrenal cortex is divided in three distinct zones; zona glomerulosa, zona faciculata 
and zona reticularis. These zones have functionally distinct roles in steroid hormone 
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production; zona glomerulosa synthesizes mineralcorticoids, zona fasciculata produces 
glucocorticoids and zona reticularis produces C19 steroids, including testosterone and 17 
β-Estradiol. The enzymes in the adrenal cortex involved in steroidogenesis include five 
forms of cytochrome P450 (CYP11A, CYP11B2, CYP17, CYP19 and CYP21) and 3β-
hydroxysteroid dehydrogenase (3β-HSD). These enzymes are distributed in the 
endoplasmatic reticulum (ER) and the mitochondria (Rainey et al. 2004). All the three 
zones use pregnenolone as substrate to synthesize their secretory products (Rainey et al. 
1994). Pregnenolone is converted from cholesterol by CYP11A in the mitochondria. 
Cholesterol can be synthesized de novo by steroidogenic tissue, but most of the derived 
cholesterol in the adrenal gland comes from receptor-mediated endocytosis of plasma low 
density lipoproteins (LDL). LDL cholesterol esters can either be stored within the cells as 
liquid droplets, or be converted directly to free cholesterol to be used in production of 
steroid hormones (Miller 1988). The cholesterol is required for the cell-membranes 
fluidity and motions, both the plasma membranes and the intracellular membranes. The 
intracellular cholesterol is mainly regulated by a group of transcription factors that 
regulate genes involved in the synthesis of cholesterol and fatty acids, called sterol 
response element binding proteins (SREBP) (Miller 2007).  
 
2.2.1 Steroidogenesis 
The full steroidogenesis is illustrated in the Fig 2.3. The first reaction where cholesterol is 
transformed to pregnenolone is the rate limiting step due to the transport of cholesterol 
from the outer to the inner membrane of the mitochondria. This transport is regulated by 
the steroidogenic acute regulatory protein (StAR) which is directly correlated with the 
steroidogenic activity in the adrenal and gonadal cells (Sugawara et al. 1995). StARs 
transportation of cholesterol is regulated by 3-hydroxy-3-methylglutaryl-CoA-reductase 
(HMGR), which is involved in the control of cholesterol biosynthesis. Progesterone is 
synthesized from pregnenolone by 3β-HSD. Progesterone can be further converted into 
11-deoxy-corticosterone by CYP21, which is converted to corticosterone by CYP11B and 
further converted to aldosterone by the same enzyme. Pregnenolone can be synthesized 
by CYP17 to 17α-OH-pregnenolone and may be further synthesized to 17α-OH-
progesterone by 3β-HSD. 17α-OH-progesterone can also be synthesized by the 
conversion of progesterone by CYP17, and is synthesized to 11-deoxycortisol by CYP21 
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and then to cortisol by CYP11B. 17α-OH-pregnenolone may be synthesized to DHEA by 
CYP17 which is converted to androstenedione by 3β-HSD. Androstenedione may be 
synthesized by conversion of 17α-OH-progesterone catalyzed by CYP17. 
Androstenedione can either be converted to testosterone by 17β-HSD or to estrone by 
CYP19. Both testosterone and estrone can be converted into 17β-estradiol by CYP19 and 
17β-HSD respectively.  
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Pregnenolone
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Progesterone
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Figure 2.3: Overview over human adrenal steroidogenesis. The boxes contain the hormones, while 
the names next to the arrow are the enzymes involved. The figure is adapted from (Gracia et al. 
2006). 
 
The production of mineralcorticoids in the zona glomerosa is regulated by angiotensin II 
(AII). The secretion of the glucocorticoids in zona fasiculata is under the control of 
ACTH, while the secretion of C19 steroids in zona reticularis is regulated by ACTH and 
forskolin (Rainey et al. 1994). 
The production of steroid hormones changes during development, during pathological 
stress and after exposure to toxicants (Oskarsson et al. 2006). 
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2.2.2 The HPA-axis 
The hypothalamus pituitary adrenal axis (HPA) is a major part of the neuroendocrine 
system in the human body. Hormones excreted from this axis control reactions to stress, 
and regulates many biologic processes, including temperature, digestion, the immune 
system, mood and emotions, sexuality and energy storage. Hypothalamus secretes the 
hormone corticotrophin-releasing hormone (CRH) which targets the anterior pituitary to 
release ACTH. ACTH stimulates the adrenal gland to produce cortisol. Cortisol is needed 
for both anabolic and catabolic metabolism, inhibition of ACTH secretion – negative 
feedback-loop, vascular reactivity, immune system and inflammatory responses. In 
addition, cortisol has effects on central nervous system and has effects on stress 
(Rosmond et al. 2000).  
 
2.2.3 Endocrine disruption 
Endocrine disrupting chemicals (EDC) has been defined as “…an exogenous substance or 
mixture that alters function(s) of the endocrine system and consequently produces adverse 
health effects in an intact organism, or its progeny, or (sub)populations” (Goksøyr 2006) 
and as “… an exogenous agent that interferes with the production, release, transport, 
metabolism, binding, action or elimination of natural hormones in the body responsible 
for the maintenance of homeostasis and the regulation of developmental processes 
(Whitehead et al. 2006).” These definitions are wide and include a great number of 
substances. The focus have mainly been on the nuclear receptor super-family, including 
the estrogen receptor and the androgen receptor, either as agonists or antagonists of 
endogenous hormones (Whitehead et al. 2006). More recently many of the chemicals 
inducing endocrine disruption have found to be non-receptor mediated. They may alter 
endocrine functions such as chemical-induced modulation of the enzymes involved in the 
production, transformation or elimination of steroid hormones. This may further alter the 
concentrations of hormones in blood and tissues. The non-receptor mediated processes 
can occur indirectly via alterations of common signal-transduction pathways, or directly 
via competitive or non-competitive inhibition of the steroid enzyme (Hecker et al. 2008). 
To summarize, the mechanisms of action of EDC are: 
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1. Agonistic/antagonistic effects – hormone mimics 
2. Disruption of production, transport, metabolism or secretion of natural hormones 
3. Disruption of production and/or function of hormone receptors 
(Goksøyr 2006) 
The conservation of the endocrine system across various species (Kavlock et al. 1996).  
There are both natural and synthetic sources of EDCs. The natural occurring sources 
include human and animal hormones and phyto- and mycoestrogens found in for example 
food, sewage and animal husbandry runoff. The synthetic sources include plastics, 
detergents, drugs, cosmetics, flame retardants, herbicides and pesticides, and industrial 
productions (Goksøyr 2006). 
 
2.3 H295R 
The human adrenocortical carcinoma cell line NCI-H295 was established from a 48-year-
old black woman from the Bahamas with a rare malignant adrenocortical carcinoma. 
Parts of the tumor were placed in culture in microwells with different types of growth 
medium. The researchers spent several years optimizing the cell culture, and ended up 
with cells with the ability to express several multiple pathways of steroidogenesis  
(Gazdar et al. 1990). The NCI-H295 cell line has shown to act pluripotent and to be 
capable to produce hormones specific for all the three zones in the adrenal gland (Rainey 
et al. 1994). It has been proved that the steroidogenetic pathways in the cell lines are 
based on expression of the same enzymes found in the normal adrenal gland  (Staels et al. 
1993a). Studies have shown that forskolin and dibutyryl cAMP enhance the production of 
cortisol, while ACTH was less effective. This indicates that the cells have a decreased 
expression of ACTH receptors (Rainey et al. 1993). The NCI-H295 cells ability to 
perform full steroidogenesis in serum-free and cholesterol-free medium, proves that 
endogenous formation of cholesterol occurs (Gazdar et al. 1990).  
The NCI-H295 cell line gave rise to another population of cells; the H295R cell line (Fig 
2.4). The difference between these cell lines is the H295Rs capability to form a tightly 
adherent monolayer in addition to a population doubling time reduced from five to two 
days (Rainey et al. 2004).  
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Due to the documentation of the adrenal gland being the most common toxicological 
target of all endocrine organs (Harvey et al. 2007), the H295R model is a useful tool in 
the assessment of EDCs. The model has several possibilities including measurement of 
hormone production (Hecker et al. 2006), gene expression (Hilscherova et al. 2004) and 
enzymatic activities of steroidogenic genes (Staels et al. 1993b). In addition, a previous 
study has described the first proteomic study on the H295R cell line (Stigliano et al. 
2008). 
  
 
Figure 2.4: Pictures of the H295R cell line obtained from the American Type Culture Collection 
(ATCC) website (www.lgcstandards-atcc.org). The picture on the left shows the cells growing at a 
low density, while the picture at the right shows the cells grown in a high density. 
 
2.4 Cell viability 
There are several assays to determine the viability of cells. In this study the alamarBlue® 
assay was used. This assay contains resazurin which is a nontoxic, cell permeable 
compound that has a blue color without fluorescent abilities. Viable cells convert this 
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compound to the fluorescent molecule resorufin (Fig 2.5). The amount of fluorescence 
produced is proportional to the number of living cells (www.invitrogen.com). 
 
 
Figure 2.5: The viability assay Alamar Blue® contains resazurin (to the left) which is converted to the 
fluorescent molecule resorufin (to the right) in viable cells. The amount of fluorescence is 
proportional to the number of viable cells. 
 
2.5 Protein chemistry 
2.5.1 Structure of proteins 
Proteins are made up by amino acids. There are in total 20 amino acids which are linked 
together by peptide bonds in many different ways, making up all the different existing 
proteins. The proteins have a three-dimensional shape, with four organization levels. The 
primary organizations is the sequence of amino acids bound together covalently with 
peptide bonds. These bonds are not broken under conditions that denature proteins, such 
as heating or high concentrations of urea. To break these bonds, the proteins have to be 
exposed over time to a strong acid or a strong base at a high temperature. The second 
organization level is the hydrogen bonds formed between the chains of amino acids, 
forming α-helixes, β-sheets or β-bends. The tertiary organization level is folding of 
domains and final arrangements of domains using disulfide bonds (-SH-bonds). While the 
final organization, the quaternary, is the organization of polypeptide subunits (Champe et 
al. 1994).   
Denaturation of proteins unfolds and disorganizes the protein’s structure without breaking 
the peptide bonds. This is usually an irreversible reaction, but in some rare cases the 
proteins can reform their originally state. Heat, organic solutions, strong acids or bases, 
detergents and ions of heavy metals can denature proteins (Champe et al. 1994). 
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The four levels of organization of the chains of amino acids are the basis of forming 
specialized functions in the final proteins; the arrangement of the fundamental structural 
elements in different combinations gives many different groups of proteins such as 
hemeproteins, fibrous structural proteins, transcription factors and enzymes among others 
(Champe et al. 1994). 
 
2.5.2 Protein synthesis 
The proteins are synthesized in the cells under management of the genome; the DNA. The 
majority of proteins are synthesized by ribosomes in the cytosol (explained below) or by 
ribosomes in mitochondria or chloroplasts. When a particular protein is needed in the cell, 
the specific DNA sequence in a chromosome that corresponds to the needed protein is 
copied into RNA. These short RNA segments are used as templates to synthesize the 
protein. The first step in transforming DNA into RNA is called transcription, and begins 
with opening and unwinding a small portion of the DNA double helix. One of the 
exposed strands of DNA is used as a template for the synthesis of RNA. The transcription 
of RNA from DNA is performed by enzymes called RNA polymerase, which catalyzes 
the formation of the phosphodiester bonds that link the nucleotides, adenine (A), cytosine 
(C), guanine (G) and thymine (T), together and thus form the sugar-phosphate backbone 
of the RNA chain. The bases are added one by one by using the DNA as template. Energy 
for this process is provided by ATP, CTP, UTP and GTP. The RNA segments used in 
protein synthesis are called messenger RNA (mRNA), ribosomal RNA (rRNA) and 
transfer RNA (tRNA) (Alberts et al. 2004).  
The conversion of RNA to proteins are called translation due to the information in RNA 
which is transformed to another language when transferred into proteins (Alberts et al. 
2004).  
The sequences of nucleotides in the mRNA are read in groups of three, which are known 
as codons. Since RNA is build up by four nucleotides, there are 4 x 4 x 4 = 64 possible 
combinations of the three nucleotides in each codon; AAA, AUG, ATG etc. Each codon 
represents a specific amino acid (Alberts et al. 2004). 
tRNA are adaptor molecules that can bind both to the codons and to amino acids. The 
enzyme aminoacyl-tRNA synthetases make sure of recognition and attachment of the 
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correct amino acid. This reaction is dependent on energy from hydrolysis of ATP (Alberts 
et al. 2004).  
The main seat in the protein synthesis is the ribosome. This is a large complex composed 
by many different proteins and several RNA molecules; rRNA. The composition is two-
thirds RNA and one-third protein. The ribosome is build up by two subunits, one smaller 
(30S), and one bigger (50S). mRNA is associated with the 30S subunit which matches the 
tRNA to the codons of the mRNA. The 50S subunit catalyzes the formation of the peptide 
bonds that link the amino acids together into a polypeptide chain (Alberts et al. 2004).  
The proteins synthesis occurs in three steps; initiation, elongation and termination. 
 Initiation: Ribosome binds to the mRNA-initiation complex; mRNA binds to 30S 
subunit and is joined by the 50S subunit. A peptide bond is formed between the 
first two amino acids. The initiation always starts with the amino acid methionine, 
represented by the codon AUG.  
 Elongation: All reactions from the first peptide bond to the addition of the last 
amino acid. 
 Termination: The completed polypeptide chain is released, and the ribosome 
dissociates from the mRNA. 
(Lewin 2008) 
The final step in the protein synthesis is the recycling of the ribosome. The ribosome is 
dissociated into its subunits, the mRNA and tRNA are released and the ribosome can be 
used in another round of translation (Noble et al. 2008).  
As described in Fig 2.6, the tRNA brings amino acids, and the growing protein chain is 
obtained by the interaction of the tRNA that brought the amino acid and the previous 
amino acid. The ribosome contains two seats for the tRNA; the A-site and the P-site. The 
A-site is for binding the incoming aminoacyl-tRNA bringing a new amino acid, while the 
P-site holds the peptidyl-tRNA which is carrying the nascent polypeptide chain. The 
peptide bond formation between the polypeptide chain and the new amino acids occurs 
when the polypeptide carried by the peptidyl-tRNA is transferred to the amino acid 
carried by the incoming aminoacyl-tRNA. This reaction is catalyzed by the 50S subunit 
of the ribosome. The result is that the peptidyl-tRNA becomes deacetylated in the P-site, 
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and the aminoacyl-tRNA becomes the new peptidyl-tRNA in the A-site. The ribosome 
moves one triplet along the mRNA – hence the new peptidyl tRNA is moved from the A-
site to the P-site, while the deacetylated tRNA in the P-site is moved to the E-site. The E-
site is occupied by the previous deactylated tRNA, which is released into the cytosol 
when the ribosome moves along the mRNA and can bring the new amino acid to be 
attached to the polypeptide chain (Lewin 2008).  
 
Figure 2.6: A brief overview over the protein synthesis. The synthesis takes place in the ribosomes. 
The ribosome is build up by proteins and RNA (rRNA). mRNA is bound to the ribosome and gives the 
code for the specific protein that is to be made. tRNA attaches to the sites in the ribosome special for 
the tRNA after bringing amino acids to the growing peptide-chain. A start codon induces the 
synthesis, while a stop codon ends the synthesis. The result is a new protein. This protein 
undergoes post-synthetic transformation and is transported to the location specific to their 
functions. Figure is obtained from (Lewin 2008). 
 
The synthesis of the polypeptide chain is terminated by one of the three stop codons 
UAA, UAG or UGA. These termination codons lie directly after the codon representing 
the C-terminal amino acid of the polypeptide chain, and are needed for termination of the 
protein synthesis (Lewin 2008). 
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There are several factors involved in the various steps of the protein synthesis. Initiation 
factors are required for all of the steps in initiation, and there are at least 12 of these 
factors that are directly or indirectly involved. Eukaryotic initiation factor 2 (eIF2) and 
eIF3 bind to the smallest ribosome subunit, eIF4A, eIF4B and eIF4F bind to the mRNA, 
and eIF1 and eIF1A bind to the ribosome subunit-mRNA complex. The elongation factor 
eEF1α mediates the entry of aminoacyl-tRNA to the A-site, while the elongation factor 
eEF2 helps translocation of the ribosome along the mRNA. The termination codons are 
recognized by protein release factors; the eukaryotic class 1 release factor, eRF1, 
recognizes all the three termination codons (Lewin 2008).   
The newly synthesized protein are transported within the cell, or out of the cell, 
associated to their final functions (Lewin 2008).  
 
2.5.3 Groups of proteins 
Proteins can be grouped by their functions. Some of these groups are described below. 
Enzymes are catalysts that increase the speed of a chemical reaction, and are not 
consumed during this reaction – thus it can be used in several following reactions. These 
proteins have an active site formed as a special pocket or a cleft where it is room for the 
substrate. This active site makes the enzymes highly specific to certain substrates. The 
catalytic efficiency says something about how long the enzymes use from catalyzing a 
reaction until the enzyme is ready for a new substrate. Some enzymes need cofactors to 
be able to perform a chemical reaction. Most enzymes can both be activated or inhibited 
by various molecules as part of a feed-back system. Enzymes can be divided into six main 
groups: Oxidoreductases, Transferases, Hydrolases, Lysases, Isomerases and Ligases 
(Champe et al. 1994). 
Structural proteins have the function to provide mechanical support to cells and tissues. 
Examples of structural proteins are:  
 collagen and elastin – constituents of extracellular matrix, form fibers in tendons 
and ligaments outside the cells 
 tubulin – forms long, stiff microtubules  
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 actin – forms filaments that underlie and support the plasma membrane 
 keratin – forms fibers that reinforce the epithelial cells, major protein in hair and 
horn 
(Alberts et al. 2004) 
Transport proteins carry small molecules or ions. Serum albumin carries lipids, and is one 
of the major transport proteins in the blood stream together with hemoglobin that carries 
oxygen and transferrin that carries iron. Some of the transport proteins are embedded in 
the membranes to carry small molecules and ions across the membrane (Alberts et al. 
2004). 
Motor proteins generate movement in cells and tissues. Two example are myosin in 
skeletal muscle cells that provides the possibility for humans to move, and kinesin that 
interact with microtubules to make organelles able to move in the cell (Alberts et al. 
2004). 
Storage proteins function is to store small molecules or ions. For example iron is stored 
bound to ferretin in the liver (Alberts et al. 2004). 
The signal proteins carry signal from cell to cell. This includes many hormones and 
growth factors that coordinate physiological functions in animals. Insulin is an example, a 
small protein that controls the glucose levels in the blood (Alberts et al. 2004). 
Receptor proteins detect signals and transmit them to the cell’s response machinery. An 
example is the insulin receptor that allows the liver cells to take up glucose in respond to 
the hormone insulin (Alberts et al. 2004). 
The function of the proteins that act as transcription factors is to bind to DNA to switch 
genes on or off. Homeodomain proteins (HMG) are part of a large group of transcriptions 
factors that are a part of controlling development in multicellular organism by acting as 
genetic switches (Alberts et al. 2004). 
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2.6 Protein analysis 
2.6.1 Two dimensional gels (2D-gels) 
A two dimensional gel electrophoresis is a combination of isoelectric focusing and 
sodium dodecylsulfat- (SDS) polyacrylamide gel electrophoresis. The proteins are 
separated according to their isoelectric point (pI) by isoelectric focusing in the first 
dimension, and by their molecular weight in the second dimension. The result is a gel 
containing numerous spots separated from each other (Adams et al. 2005).  
The isoelectric focusing is a method to separate the proteins according to their isoelectric 
point (pI). Due to proteins amphoteric nature – they carry either positive, negative or zero 
net charge depending on the pH in the surroundings – they have an isolelectric point (pI) 
at a specific pH where the net charge is zero. Below their pI, the proteins are positively 
charged, and above their pI, the proteins are negatively charged. In isoelectric focusing, 
the pH gradient is an important factor because the proteins will migrate to the point where 
their net charge is zero. Hence, proteins with a positive net charge will migrate towards 
the anode, and proteins with a negative net charge will migrate towards the cathode 
(Adams et al. 2005). 
The second dimension is usually performed on polyacrylamide gels with denaturing 
conditions obtained by using an anionic detergent such as SDS. The polyacrylamid gels 
are generated by polymerization of acrylamide monomers into long chains. These long 
chains form cross-links between bifunctional compounds such as N, N-methylene 
bisacrylamide (bis) and free functional groups at chain termini. The pore size of the gel is 
determined by the concentrations of acrylamide and bisacrylamide – higher acrylamid 
concentrations gives smaller pore size. The anionic detergents such as SDS denaturate 
and unfolds the proteins by wrapping around the hydrophobic parts of the protein. The 
SDS-protein complexes are highly negatively charged, and migrated through the gel 
based on their size rather than by their charge. If a reducing agent such as dithiothreitol 
(DDT) is added to the system, the denatured proteins are completely unfolded (Invitrogen 
2003). 
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2.6.2 Liquid chromatography – tandem mass spectrometry (LC-MS/MS) 
Liquid chromatography is used to separate substances based on their characteristic 
polarities and their interaction with the stationary phase. The separation is based by the 
distribution between a stationary phase and a liquid, mobile phase. The system is build up 
by several components; a column (the stationary phase), a solvent (the mobile phase), a 
pump, an injector and a detector. The mobile phase will carry the analytes in the sample 
past through the column – the stationary phase. As the mobile phase flows through the 
column, the analytes in the sample will distribute between the two phases. Analytes with 
more affinity to the column will be held back and travel slowly through the stationary 
phase, while analytes with lower affinity for the stationary phase will travel faster. This 
separates the analytes with high affinity for the stationary phase from the analytes with 
lower affinity for the stationary phase. If an analyte have a very strong affinity for the 
stationary phase, the physical or chemical nature of the mobile phase must be changed to 
displace the analyte from the stationary phase to be able to separate analytes in a sample 
(Burtis et al. 2001).  
Mass spectrometry (MS) is a method where the target molecule first is ionized into ions 
with a specific mass-to-charge (m/z) ratio, and then the ions are measured and separated. 
The result is a mass spectrum where each ions m/z ratio is plotted against the relative 
abundance in the sample. This data is used to determine structure and concentrations of 
inorganic and organic compounds. It has been more difficult to combine MS with liquid 
chromatography than with gas chromatography because the analytes are solved in a 
liquid, while the mass spectrometer requires the analyte to be in the gas phase. Four 
elements have been used to help the possibility to combine liquid chromatography and 
MS; nebulization of the liquid phase, removal of the bulk solvent, dissociation of the 
solvent-analyte clusters and ionization of the analytes. This has made the combination of 
liquid chromatography and MS much easier, and the result is production of ions with 
minimal fragmentation due to soft ionization (lower energy) (Burtis et al. 2001).  
MS requires a transformation of a neutral atom or molecule to an ion created by an 
ionization step. Many techniques can be used, but for proteins and peptides electrospray 
ionization (ESI) is a common method. ESI which is most effective for ionic or extremely 
polar compounds, is able to ionize macromolecules and able to produce multiple charged 
ions (Burtis et al. 2001). ESI produce charged droplets by passing a solubilized sample 
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through a high voltage needle at atmospheric pressure. Prior to the entry of the mass 
spectrometer, desolvation of the samples occurs (Wysocki et al. 2005). The mass analyzer 
separates the ions according to their m/z ratio before the ions reach the detector. There are 
several different types of mass analyzers such as magnetic-sector, quadropole mass filter, 
quadropole ion trap, time-of-flight and ion cyclotron analyzers (Burtis et al. 2001).  
An ion trap stores the ions and this capability is used when two or more mass analyzers 
are operated in tandem. Tandem mass spectrometry (MS/MS) is a technique where mass-
specific isolations are done several times in continuous operations. The targeted 
compound is ionized selectively, and its ions are separated from the other compounds. 
The selected ions collide with molecules of a neutral gas in a collision chamber resulting 
production of fragments to be separated and identified in the second spectrometer (Burtis 
et al. 2001). The first mass-selective ion separated is called the parent ion. The second 
operation is to determine the mass/charge ratio of the fragment ions produced by 
collision-induced dissociation of the parent ions (March 1997).  
The separation of proteins and peptides by chromatography before reaching the mass 
spectrometer, helps detecting more ions.  
The identification of proteins using mass spectrometry requires interplay between how 
molecules are ionized, activated and detected, and the gas phase peptide chemistry – 
which bonds are broken, at what rate, and how cleavage depends on factors such as 
peptide/protein charge state, size, composition and sequence (Wysocki et al. 2005).  
 
2.6.3 Western Blot 
Western blot is a technique that detects proteins in a given sample of proteins extracted 
from tissue or cells. The proteins are separated by gel electrophoresis by the length of the 
polypeptides. Secondly the content on the gel is transferred to a membrane, and the 
proteins are detected by using antibodies specific to target proteins. The targeted proteins 
are detected by for example a fluorescent secondary antibody. After detection, the 
proteins can be quantified to see how much is accumulated (Burtis et al. 2001).  
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3. Material and methods 
All the equipments, kits, chemicals, commercial buffers, instruments and softwares are 
listed in Appendix 1 together with manufacturer. Thus this will not be mentioned in the 
description of material and methods. 
 
3.1 Cell-line and cultivating cells 
The human adenocarcinoma cell-line H295R was obtained from the American Type 
Culture Collection. The cells were cultivated in 75 cm2 flasks with 12.5 ml of 
supplemental medium at 37 °C with a 5 % CO2 atmosphere. The cells were grown in a 
1:1 mixture of Dulbecco’s Modified Eagles Medium and Ham’s F-12 Nutrient mixture 
(DMEM/F12) supplemented with 5 ml/l of ITS+ Premix, and 12.5 ml/l of BD Nu-Serum 
as described earlier (Gracia et al. 2006; Hecker et al. 2006). The medium was refreshed 
three times a week and sub cultured once a week to maintain cell density and viability. 
The cells were detached with 2 ml 0.25 % trypsin/0.53 nM EDTA. The detached cells 
were added to 10 ml medium and centrifuged at 1250 rpm in 5 minutes. The pellet was 
resolved in medium, filtered through a 70 µM Cell strainer and cultured in 75 cm2 flasks. 
Cells between passage 5 and 13 were used in the experiment. 
 
 
  
Figure 3.1: Illustration of culturing the H295R cells. The picture to the left shows the sterile cabinet 
where all the treatment, changing of medium and subculturing of the cells were done. The picture to 
the right shows the microscope used when checking the cells viability and counting the number of 
cells.   
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3.2 Test chemicals 
Tetrabutylammonium heptadecafluorooctanesulfonate and perfluorononanoic acid were 
purchased in powder form from Sigma-Aldrich with a purity of >95% and >97% 
respectively. Chemicals were dissolved in DMSO to 600nM stock solutions and stored in 
aliquots at -20°C. DMSO 0.1% was used as a solvent control for PFNA, while 
tetrabutylammonium cloride (TBA) solved in DMSO 0.1 % were used as a combined 
solvent and salt control for PFOS. The reason for using a separate control for PFOS was 
that PFOS were purchased as a tetrabutylammonium-salt. TBA was also compared to 
DMSO to check whether the salt had an effect by itself.   
 
3.3 Experimental design 
The experiment of a PhD student (Kraugerud et al. 2010, manuscript in preparation) was 
used as template when the experimental design was decided. In her study, 24-well plates 
were used, and the lowest concentration without toxic effects for PFOS was 600 µM and 
for PFNA 60 µM. Because of the need of a larger amount of cells to obtain enough 
proteins for the proteomic analysis, the experiment was conducted in 75 cm2 flasks. A 
consequence of changing from 24-well plate to 75 cm2 flasks was that the ratio between 
medium and cells hence the ratio between the amount of the compounds and cells, 
changed. On basis of this, new concentrations were calculated (shown in the table below) 
to match the amount of compounds per cell used in the previous experiment. The density 
of cells used in earlier experiments performed in 24-well plates were 150 000 cells per 
cm2; each well has a surface of 2cm2 and holding 1 ml of medium. 
Table 3.1: This table shows calculations needed from transformation of a dose-response experiment 
done in 24-well plate to an experiment in 75 cm2 flasks, to be able to have similar effects as the 
previous experiment. 
Culture 
Vessel 
Culture 
Surfac
e (cm2) 
cells/cm
2 
Total 
Amount 
of Cells 
in Vessel 
Mediu
m 
Volume 
(ml) 
Exposure 
Concentratio
n (µM) 
Total 
Amoun
t 
(µmole) 
µmol/cell 
Plate (24-well) 2 150000 300000 1 60 0,06 2,00E-07
Plate (24-well) 2 150000 300000 1 600 0,6 2,00E-06
Flask (T75) 75 150000 11250000 12,5 60 0,75 6,67E-08
Flask (T75) 75 150000 11250000 12,5 600 7,5 6,67E-07
Flask (T75) 75 150000 11250000 12,5 300 3,75 3,33E-07
Flask (T75) 75 150000 11250000 12,5 200 2,5 2,22E-07
Flask (T75) 75 150000 11250000 12,5 175 2,1875 1,94E-07
Flask (T75) 75 150000 11250000 12,5 150 1,875 1,67E-07
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The cells were detached as described above and resuspended in medium. The number of 
cells was counted by using a Bürker haematocytometer. 4x4 squares were counted, 
multiplied by two and multiplied by the volume of medium added. After counting, the 
cells were seeded in the 75 cm2 flasks at a density of 150.000 cells per cm2. The cells 
were exposed to the compounds 24h post seeding. The test compounds, dissolved in 
DMSO 0.1%, were added to 12.5 ml of medium to give final concentrations of 150µM, 
175µM and 200µM for each compound, including the salt control (TBA). Medium 
containing the compounds was added to the cells. After 48 h, medium was collected and 
stored at -80 °C for future hormone analysis. The cells were detached as described earlier, 
and the cell pellets were kept on ice until a lysis buffer (RLT) from Allprep® 
DNA/RNA/Protein Mini Kit was added to the vials (see further description of isolation 
below).  
 
3.4 Viability 
The viability was controlled visually under a microscope, both 24 h post exposure and 48 
h post exposure. The labels on the Tissue Culture flasks were hidden to make the visual 
observations less biased by not knowing which exposure group that was looked at. To be 
able to observe any visual effects of the exposures, controls were used in every single 
experiment.  
In addition to visual evaluation, the alamarBlue® Assay was performed on the cells to 
measure the viability of the cells after exposure. This assay quantifies the proliferation of 
cells by measuring how much of the reagent is reduced after incubation due to metabolic 
activity. It is commonly used to check relative cytotoxicity of compounds. After 48 h 
exposure, the medium was collected and frozen at -80 °C, and replaced with 11.25 ml 
fresh medium mixed with 1.25 ml alamarBlue®, giving a final concentration of 10 % 
alamarBlue®. The cells were incubated for three hours under the same conditions as 
described above. After incubation, the medium was transferred to 96-well plates, and read 
at 570 nm and 600 nm by a spectrophotometer. The percent viability of the control was 
calculated according to the manufactures instructions. 
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The viability assay, alamarBlue®, was done on a separate experiment due to the risk of 
the reagent in the assay influencing the cells to be isolated. This means that the viability-
data is not from the exact same cells that have been isolated and analyzed. 
The general tendency showed that the flasks where the cells were exposed to PFOS had a 
lower density compared to DMSO 0.1 %, TBA and PFNA. In a few of the experiments, 
all the cells were dead, and these cells have been excluded from further analysis and 
statistics. 
 
3.5 Isolation of RNA, DNA and proteins 
Isolation of RNA, DNA and proteins was done by using Allprep® DNA/RNA/Protein 
Mini Kit. The manufacturer’s protocol was followed, except during resolving the protein-
pellet (see description below). In addition, Phosphatase Inhibitor Cocktail 1, Phosphatase 
Inhibitor Cocktail 2 and Protease Inhibitor Cocktail was added to the buffer RLT (10 µl 
of each cocktail/1000 µl buffer RLT).  
Before starting the protocol, β-mercaptoethanol was added to the RLT buffer (10µl/mL), 
and 96-100 % ethanol was added to Buffer RPE, Buffer AW1 and Buffer AW2, as 
described in the manufacturer’s protocol. In addition, the Buffer EB was preheated to 
reach 70 °C. 
The cells were trypsinized with 2 ml 0.25 % trypsin/0.53 nM EDTA to detach them from 
the flasks. Medium was added to inactivate the trypsin/EDTA, and the cells were 
centrifuged to form a pellet. To lyse the cells, 1 ml buffer RLT, containing the cocktail as 
described above, was added to the cell pellets from each 75 cm2 flask. The mixture of 
buffer and cells were vortexed and added to Qia Shredder columns.  Lysate from one 75 
cm2 flask was divided into two Qia Shredder columns due to the high content of cells in 
each flask. The Qia Shredder columns were centrifugated at full speed for 2 minutes. The 
flow-throughs were transferred to AllPrep DNA spin-columns, and centrifuged at 10000 
rpm for 30 seconds to separate the DNA from the RNA and the proteins. The DNA 
attaches to the AllPrep DNA spin-columns, and they were placed in new tubes in the 
fridge for later DNA purification. 
The flow-through containing the RNA and the proteins were washed by adding 400 µl of 
96-100% ethanol and mixing well without centrifugation. The samples were transferred to 
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AllPrep RNA spin columns, and centrifuged for 15 seconds at 10000 rpm. The RNA 
attaches to the column, and the flow-throughs containing the proteins were transferred to 
another tube and stored in the fridge for later precipitation. The AllPrep RNA spin 
columns were washed by adding 700 µl Buffer RWI, centrifuging at 10000 rpm for 15 
seconds, adding 500 µl Buffer RPE and centrifuging at 10000 rpm for 15 seconds. The 
Buffer RPE was added a second time, and the samples were centrifuged at 10000 rpm for 
2 minutes. The flow-throughs between each washing-step were gently discarded, to 
prevent contamination of the samples. After the washing-steps, the columns were 
transferred to new tubes and centrifuged at full speed for 1 minute to remove all left-over 
liquid. The columns were transferred to new vials, and the RNA was eluted by adding 50 
µl dH2O to each column and centrifuging at 10000 for 1 minute. RNA originating from 
the same flask were collected in the same vial and stored at -80 °C. To avoid thawing the 
samples unnecessarily, 5 µl RNA was kept in a separate vial to measure the RNA content 
by NanoDrop. 
To precipitate the proteins, 1 mL Buffer APP was added to each of the flow-throughs 
after the AllPrep RNA spin columns. The vials were incubated in room temperature for 
10 minutes and then centrifuged at full speed for another 10 minutes. The pellets were 
washed by adding 500 µl 70 % ethanol followed by mixing and centrifugation at full 
speed for 1 minute. After washing, the pellets were carefully dried by decant the 
supernatant, centrifuging one more time at full speed for 1 minute and removing the 
excess liquid with a pipette. The pellets were dried for maximum 5 minutes in room 
temperature. Due to the proteomic protocol (described below), the protein pellet was 
resolved in 100 µl Modified reswell solution (Appendix 2) after the drying step and not 
the buffer ALO the Allprep® DNA/RNA/Protein Mini Kit provides. The pellets were 
incubated with Modified reswell solution while purifying the DNA, to completely 
dissolve the pellet. The dissolved pellets from the same flask were collected in the same 
vial and were stored at -80 °C. For quantification, 5 µl of the dissociated protein were 
kept in a separate vial to avoid thawing the samples unnecessarily.  
The AllPrep DNA spin columns were washed by adding 500 µl Buffer AWI, centrifuged 
at 10000 rpm for 15 seconds, and then 500 µl Buffer AW2 followed by centrifuging at 
full speed for 2 minutes. The flow-throughs were discarded between the washing-steps. 
The DNA was eluted with 100 µl preheated EB buffer supplied by the Allprep® 
DNA/RNA/Protein Mini Kit for each vial. DNA originating from the same flask were 
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collected in the same vial and stored at -80 °C. To avoid thawing the samples 
unnecessarily, 5 µl DNA was kept in a separate vial to measure the DNA content by 
NanoDrop. 
 
3.6 Protein quantification 
The protein content was measured by using RC DC Protein Assay. Standards were made 
from the stock solution of bovine serum albumin from the kit. The dilutions are shown in 
Appendix 3. Quality controls were made from BSA in two concentrations, one in the 
higher range, 1.38 mg/ml, and one in the lower range, 0.376 mg/ml, of the standard curve, 
and diluted in dH2O. Due to expected high concentrations, the samples were diluted 1:20 
in dH2O before the assay. The manufacturer’s Microfuge Tube Assay Protocol was 
followed. The standards, controls and samples were firstly precipitated by adding 25 µl 
sample and 125 µl Reagent I to each vial. After incubating the vials at room temperature 
for 1 minute, 125 µl Reagent II was added. The vials were vortexed to mix the samples 
after adding the regents. To gather the proteins in pellets, the vials were centrifuged at full 
speed for 5 minutes. The pellets were dried and dissolved in 127 µl Reagent AS, which 
was made by adding 5 µl solution S to 250 µl solution A. The vials were incubated at 
room temperature for 5 minutes, or until the pellets were resolved. Finally, 1 ml Reagent 
B was added to each vial, and incubated in room-temperature for at least 15 minutes at 
room temperature to promote a color reaction in the vials. The color is stabile for 1-2 
hours after adding Reagent B. The absorbance was read at 750 nm by a UV/VIS 
spectrophotometer. After reading the absorbance, a standard curve was made, and the 
protein concentration in each sample was calculated. The standard curves and the 
calculations of the concentrations are shown in Appendix 4. 
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3.7 Endocrine effects – hormone quantification 
To measure hormone concentrations in thawed, collected medium, solid phase 
radioimmunoassay (RIA) kits were used. Standards were made by diluting the hormone 
for each hormone assay in cell culture medium. All the standards, controls and samples 
were duplicated and an average was calculated for each sample.  
 
3.7.1 Estradiol 
To measure estradiol concentrations, Coat-A-Count Estradiol kit, was used. Of each of 
the thawed medium samples, standards and controls, 100 µl was added to coated tubes 
provided by the kit. Directly after this, 1 ml of 125I Estradiol was added to each vial. The 
samples were vortexed and incubated at room temperature for 3 h. After incubation, the 
tubes were decanted thoroughly and left draining for 5-10 minutes. The vials were 
counted for 1 minute in a gamma counter.  
The standard-curve consisted of 6 standards and a reference, with the concentrations as 
follows: reagent blank, medium blank, 10 pg/ml, 40 pg/ml, 100 pg/ml, 250 pg/ml, 1000 
pg/ml and 4000 pg/ml. The sensitivity of the assay was 10 pg/ml and the interassay 
variation coefficient was 10.02 %. 
 
3.7.2 Testosterone 
To measure testosterone concentrations, Coat-A-Count Total Testosterone kit, was used. 
Of each of the thawed medium samples, standards and controls, 50 µl was added to 
coated tubes provided by the kit. Directly after this, 1 ml of 125I Total Testosterone was 
added to each vial. The samples were vortexed and incubated at 37 °C for 3 h. After 
incubation, the tubes were decanted thoroughly and left draining for 5-10 minutes. The 
vials were counted for 1 minute in a gamma counter.  
The standard-curve consisted of 6 standards and a reference, with the concentrations as 
follows: reagent blank, medium blank, 0.1 ng/ml, 0.5 ng/ml, 2.5 ng/ml, 10 ng/ml and 20 
ng/ml. The sensitivity of the assay was 0.08 ng/ml and the interassay variation coefficient 
was 7.08 %. 
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3.7.3 Progesterone 
To measure progesterone concentrations, Spectria Progesterone RIA kit, was used. Of 
each of the thawed medium samples, standards and controls, 50 µl was added to coated 
tubes provided by the kit. Directly after this, 500 µl prediluted tracer was added to each 
vial. The samples were vortexed and incubated at room temperature for 2 h. After 
incubation, the tubes were decanted thoroughly and left draining for 5-10 minutes. The 
vials were counted for 1 minute in a gamma counter.  
The standard-curve consisted of 6 standards and a reference, with the concentrations as 
follows: reagent blank, medium blank, 0.5 ng/ml, 1.5 ng/ml, 4 ng/ml, 10 ng/ml and 40 
ng/ml. Because of an error in making the standards, a standard-curve from a previously 
run was used. This does not give exact amounts of progesterone in the samples, but it will 
give an indication if there are any differences in levels in the different exposures.  
 
3.7.4 Cortisol 
To measure cortisol concentrations, Coat-A-Count Cortisol kit, was used. Of each of the 
thawed medium samples, standards and controls, 25 µl was added to coated tubes 
provided by the kit. Directly after this, 1 ml of 125I Cortisol was added to each vial. The 
samples were vortexed and incubated at 37 °C for 45 minutes. After incubation, the tubes 
were decanted thoroughly and left draining for 5-10 minutes. The vials were counted for 
1 minute in a gamma counter.  
The standard-curve consisted of 6 standards and a reference, with the concentrations as 
follows: reagent blank, medium blank, 10 ng/ml, 50 ng/ml, 100 ng/ml, 200 ng/ml and 500 
ng/ml. The sensitivity of the assay was 2.5 ng/ml and the interassay variation coefficient 
was 9.99 %. 
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3.8 Sample preparations methods for 2D electrophoresis and 1D electrophoresis 
The protein samples from each group were pooled to reach a final amount of proteins of 
800 µg. Equal quantities of proteins were taken from each sample to make the pools’ 
content representative to all the replicates, as shown in table 3.2. 
 
Table 3.2: Overview over the amount of each protein sample isolated from exposed H295R cells used 
to make pools for proteomic analysis. Each replicate protein samples’ concentration is shown in the 
second column. The volumes to be taken out from each sample, were calculated by dividing 800 on 
the number of samples, and divide that number on the protein samples’ concentrations. 
Dose Conc (µg/µl) V for a tot 800 µg Tot volume (µl) 800/x 
0,1 % DMSO 29,86 5,36   160,00 
0,1 % DMSO 7,36 21,74   160,00 
0,1 % DMSO 15,46 10,35   160,00 
0,1 % DMSO 18,48 8,66   160,00 
0,1 % DMSO 21,76 7,35   160,00 
      53,46   
          
PFOS 175 µM 9,23 28,89   266,67 
PFOS 175 µM 9,12 29,24   266,67 
PFOS 175 µM 4,65 57,35   266,67 
      115,48   
          
PFOS 200 µM 5,57 47,88   266,67 
PFOS 200 µM 9,37 28,46   266,67 
PFOS 200 µM 4,96 53,76   266,67 
      130,10   
          
TBA 175 µM 15,35 17,37   266,67 
TBA 175 µM 8,12 32,84   266,67 
TBA 175 µM 15,61 17,08   266,67 
      67,30   
          
TBA 200 µM 12,27 21,73   266,67 
TBA 200 µM 16,33 16,33   266,67 
TBA 200 µM 11,38 23,43   266,67 
      61,50   
          
PFNA 175 µM 10,44 19,16   200,00 
PFNA 175 µM 9,41 21,25   200,00 
PFNA 175 µM 10,04 19,92   200,00 
PFNA 175 µM 21,08 9,49   200,00 
      69,82   
          
PFNA 200 µM 17,22 15,49   266,67 
PFNA 200 µM 10 26,67   266,67 
PFNA 200 µM 16,27 16,39   266,67 
      58,54   
 
The pools were precipitated by using ReadyPrepTM 2-D Cleanup Kit according to the 
manufacturer’s instructions. The proteins in the pools were precipitated by adding 300 µl 
precipitating agent 1, followed by 15 minutes incubation on ice, and adding 300 µl 
precipitating agent 2. The samples were mixed well, and to form tight pellets, the samples 
were centrifuged at maximum speed for 5 minutes. The supernatants were removed 
before centrifuging a second time at maximum speed for 15-30 seconds. After 
centrifugation, the pellets were washed by adding 40 µl wash reagent 1 followed by 
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centrifugation at maximum speed for 5 minutes. The wash reagent was removed by using 
a pipette, and 25 µl of ultra pure water was added followed by centrifugation and 
discarding the supernatant. Prechilled Wash reagent 2 was added to the pellets, 1 ml wash 
reagent 2 added 5 µl of wash additive to each sample, and the vials were incubated at -
20°C for 30 minutes. The vials were vortexed every ten minutes during the incubation 
time. After incubation, the samples were centrifuged at full speed for 5 minutes to form 
tight pellets. The supernatant was discarded, and the pellets were carefully dried in room 
temperature and resolved in 200 µl IPG Reswell buffer. To clarify the protein samples, 
the vials were centrifuge at maximum speed. To run 1D SDS-PAGE, 20 µl was taken out 
from each protein pool. Mixtures were made by adding 5 µl 3x Dissociation Buffer (see 
Appendix 5 for details) per 10 µl protein extract. The mixtures were heated at 100 °C in a 
heating block for 5 minutes.  
 
3.9 One dimensional electrophoresis 
 
 
 
Figure 3.2: Flow chart for one dimensional gel electrophoresis. The figure is obtained from the 
internal manual at the Aberdeen Proteome Facility, Institute of Medical Sciences, University of 
Aberdeen. 
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The pools were analyzed by polyacrylamid slab gels to determine the amount of the 
protein samples from the cells to be loaded on the 2D gels. To each of the wells, 3 µl of 
protein mixture, described above, were added. The samples were run on duplicated gels. 
The gels were stained by using Colloidal Coomassie Blue G250 (Cash et al. 1995). The 
gels were fixed overnight in the Gel Fix solution (for description see Appendix 5) after 
electrophoresis. The gels were washed three times for 30 minutes each wash in MilliQ 
water, and equilibrated in one hour in room temperature by adding gel equilibrating 
solution (for description see Appendix 5) to the gels. After the equilibration, 0.2 g 
Coomassie Brilliant Blue G250 powder per 200 mL of gel equilibration solution was 
added directly to the gels. The gels were stained for up to four days, and scanned either 
wet or dry by using ImageScanner TM III. 
 
Table 3.3: Overview of amount of protein-sample from exposed H295R cells added to two-
dimensional gels after checking the band-strengths on a one-dimensional gel. The amount of IPG 
reswell buffer was adjusted according to the amount of sample added to the gel to give a final 
volume of 140 µl. 
Sample Amount sample added to gel (µl) Amount IPG reswell buffer (µl) 
DMSO 0,1% 20 120 
TBA 175 20 120 
TBA 200 18 122 
PFOS 175 20 120 
PFOS 200 20 120 
PFNA 175 15 125 
PFNA 200 18 122 
 
 
3.10 Two dimensional gel electrophoresis (2D-gel) 
3.10.1 First dimension 
From the pooled samples, 100 µg of total protein was added to 7 cm Immobiline™ 
DryStrips pH 3-10 NL as described earlier by (Cash et al. 2003; Uwins et al. 2006). These 
DryStrips separate the proteins in the first dimension, by isoelectric pH (PI) in a non-
linear range from pH 3 to 10. That means that the DryStrips can catch both the smaller 
and the larger proteins, but also are able to maintain a good separation of the medium 
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sized proteins, which are the majority. The samples were added to the IPG Reswelling 
Cassette, and the DryStrips were carefully lowered into the sample without creating air 
bubbles. The DryStrips were covered and left overnight to rehydrate, and then 
electrophoresed as shown in the table 3.4. 
 
Table 3.4: The electrophoresis conditions for 7 cm Immobiline™ DryStrips pH 3-10 NL to separate the 
proteins in the first dimension by isoelectric pH. The current and power were held constant at 2mA 
and 5W, respectively.  
Step Voltage Time 
1 200 V 1 min 
2 3500 V 90 min
3 3500 V 65 min
 
The blue color in the Reswell solution will move towards the anode, and due to this it is 
possible to see if the proteins are being separated. After electrophoresis, the strips can 
either be frozen down at -20°C or continue to the equilibration step followed by the 
second dimension.  
The DryStrips were equilibrated 30 minutes in IPG equilibrating buffer containing 10 
mg/ml DTT on a rotary shaker, and 30 minutes in IPG equilibrating buffer containing 25 
mg/ml iodoacetamide. The DryStrips were drained and rinsed in MilliQ water, and loaded 
to the second dimension.  
 
3.10.2 Second dimension 
For the separation by mass in the second dimension, precasted commercial gels, ZOOM® 
Gels were used. The electrophoresis running buffer was prepared by adding MOPS 20X 
concentrate buffer to MilliQ water (described in Appendix 5). The inner running buffer 
was added antioxidant to trigger the electrophoresis reaction. The precasted gel was taken 
out of the protective bag, the comb was removed, and the gel and and the wells were 
rinsed with MilliQ water followed by a brief rinse by the running buffer. The gel was 
assembled with a belonging tank which was filled with running buffer and placed on an 
electric stirrer. The IPG strips were loaded to the gels, one strip per gel. On each gel, 
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there is a side track where a molecular weight marker (SeeBlue Plus 2) was added to the 
gel. The running conditions used were as follows: 
 Step 1: Time 30 minutes, voltage 100V, current 35 mA and power 5W 
 Step 2: Time 1:15 hour, voltage 200V, current 35 mA and power 5W 
The molecular weight marker was used as an indicator on how electrophoresis run was 
proceeding. At the end of the electrophoresis, the gels were taken out of the chamber. The 
corners were cut in a pattern to be recognized later on, and transferred to a tray containing 
a gel fixer on a shaker. Four replicate gels were run for each pool of proteins. 
 
3.11 Post electrophorestic detection of proteins 
Proteins were detected by staining the gels with Colloidal Coomassie Blue G250 as 
described above under the description of one dimensional electrophoresis. 
 
3.12 Gel imaging 
The gels were scanned wet by using ImageScanner TM III. The scanner runs from the 
LabScan software. The parameters were set like in the table 3.5. 
Table 3.5: Parameters set in LabScan software connected to the ImageScanner TM III when scanning 
the 2D-gels. 
Mode Transparent 
Resolution 600 dpi 
Color Green filter 
 
The gels were dried between to sheets of cellophane for long term storage by using 
EasyBreeze Gel Drier. 
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3.13 Spot analysis 
The images were transferred to Progenesis Samespots v 3.3. This software were used to 
detect and quantify proteins spots, expressed as normalized volumes. The software was in 
addition used to match the profiles across the gel series. The image below (Fig 3.3) shows 
the gel used as a reference gel in the experiment. It was chosen because it was the clearest 
image. 
 
 
Figure 3.3: The proteomic profile of the H295R cell line. On the right, there is a molecular weight 
marker to be able to determine the size of the proteins. The pH ranges non-linear from 3-10 from left 
to right. This gel was used as a reference gel in the experiment. 
 
Progenesis Samespots v 3.3 calculated p-values and fold change. These were used to 
choose spots to be further analyzed. Spots with p ≤ 0.05 and a fold change>2 were 
identified by using 2D-gels and LC-MS/MS. The spot volumes were also analyzed by 
using JMP8 software, since the fold change values calculated from the Progenesis 
Samespot v 3.3 software are between the two groups with the largest difference and not 
necessarily between exposed groups and control. The calculated values from the 
Progenesis Samespot v 3.3 software are shown in the table 3.6.  
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Table 3.6: Calculated Anova (p-values) and fold change calculated by Progenesis software. The 
spots are ranked based on Anova (p-value), with the lowest p-value at the top.  
Average normalized volumes Spot 
number 
Anova (p) Fold 
DMSO PFNA 175 PFNA 200 PFOS 175 PFOS 200 TBA 175 TBA 200 
949 1,780E-13 3,1 5,743E+06 1,121E+07 1,355E+07 9,987E+06 1,203E+07 4,417E+06 4,958E+06
501 1,158E-10 3,1 7,962E+06 7,092E+06 5,867E+06 3,519E+06 2,985E+06 8,723E+06 9,314E+06
1033 3,777E-10 3,9 3,678E+06 2,141E+06 1,759E+06 6,897E+06 5,293E+06 2,986E+06 3,979E+06
1277 1,167E-08 2,2 7,904E+06 1,241E+07 1,255E+07 1,216E+07 1,367E+07 6,930E+06 6,254E+06
897 9,527E-08 2,1 5,590E+06 1,175E+07 9,708E+06 9,966E+06 1,155E+07 5,659E+06 5,603E+06
974 1,747E-07 3,2 2,781E+06 1,956E+06 1,520E+06 4,666E+06 4,868E+06 2,632E+06 3,973E+06
972 3,346E-07 2,9 1,620E+06 2,868E+06 4,240E+06 2,497E+06 2,139E+06 1,450E+06 1,815E+06
896 1,713E-06 2,1 4,897E+06 8,725E+06 8,564E+06 8,618E+06 9,261E+06 4,348E+09 4,403E+06
1502 5,800E-06 2,2 1,513E+07 1,735E+07 2,226E+07 1,747E+07 1,586E+07 1,488E+07 1,022E+07
953 1,244E-05 2,4 4,314E+06 6,274E+06 6,428E+06 5,622E+06 6,871E+06 2,816E+06 3,260E+06
496 2,107E-05 2,0 3,961E+06 3,578E+06 2,824E+06 2,557E+06 2,283E+06 4,402E+06 4,491E+06
1288 2,274E-05 2,0 4,339E+06 6,117E+06 6,040E+06 7,503E+06 8,849E+06 4,770E+06 4,460E+06
523 2,790E-05 2,0 1,398E+06 1,197E+06 9,493E+05 7,297E+05 7,673E+05 1,419E+06 1,443E+06
1323 1,022E-04 2,3 3,759E+06 5,839E+06 4,238E+06 4,850E+06 4,347E+06 4,613E+06 2,496E+06
1208 2,005E-04 2,7 4,583E+06 3,932E+06 2,455E+06 1,973E+06 1,714E+06 4,236E+06 3,270E+06
853 2,206E-04 2,5 8,602E+06 9,871E+06 4,584E+06 1,104E+07 1,149E+07 9,962E+06 9,778E+06
644 1,100E-02 2,0 5,448E+06 6,922E+06 6,860E+06 7,500E+06 8,346E+06 4,170E+06 6,203E+06
 
The normalized volumes were the basis for electing which spots to excise. In addition 
each spot was assessed by looking at quality of the spots. This was done to see whether 
the characterization as a spot done by the software was real, or if there was contamination 
of ultrafine particles present. The quality was considered as good if the spot had a distinct 
peak, and if it was limited to a smaller area and not forming streaks.  
 
3.14 Gel digestion 
Following 2-D gel electrophoresis, proteins were visualised using colloidal Coomassie 
Brilliant Blue G-250 staining (as mentioned above) and the protein spots of interest 
excised from the gel. Proteins in the gel pieces were digested with trypsin using an 
Investigator ProGest robotic workstation. Briefly, proteins were reduced with DTT (60°C, 
20 min), S-alkylated with Iodoacetamide (25°C, 10 min) and then digested with trypsin 
(37°C, 8 h). The resulting tryptic peptide extract was dried by rotary evaporation and 
dissolved in 0.1% formic acid for LC-MS/MS analysis.  
 
This procedure was done by Liz Stewart at Aberdeen Proteomics, Institute of Medical 
Science, University of Aberdeen. The buffers and solutions used in this procedure are 
listed in Appendix 6. 
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3.15 Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/MS) 
Peptide solutions were analysed using an HCTultra PTM Discovery System coupled to an 
UltiMate 3000 LC System. Peptides were separated on a Monolithic Capillary Column 
(200 μm i.d. x 5 cm; Dionex part no. 161409)  
 
Eluent A was 3% acetonitrile in water containing 0.05% formic acid, Eluent B - 80% 
acetonitrile in water containing 0.04% formic acid with a gradient of 3% - 45% B in 12 
minutes at a flow rate of 2.5μL/min. 
 
Peptide fragment mass spectra were acquired in data-dependent AutoMS(2) mode with a 
scan range of 300-1500 m/z, 3 averages, and up to 3 precursor ions selected from the MS 
scan 100-2200 m/z). Precursors were actively excluded within a 1.0 min window, and all 
singly charged ions were excluded. 
 
This procedure was done by Liz Stewart at Aberdeen Proteomics, Institute of Medical 
Science, University of Aberdeen. The buffers and solutions used in this procedure are 
listed in Appendix 6. 
 
3.16 Search for proteins 
Peptide peaks were detected and deconvoluted automatically using Data Analysis 
software. Mass lists in the form of Mascot Generic Files were created automatically and 
used as the input for Mascot MS/MS Ions searches of the NCBInr database using the 
Matrix Science web server (www.matrixscience.com). The default search parameters 
used were: Enzyme = Trypsin, Max. Missed cleavages = 1; Fixed modifications = 
Carbamidomethyl (C); Variable modifications = Oxidation (M); Peptide tolerance ± 1.5 
Da; MS/MS tolerance ± 0.5 Da; Peptide charge = 2+ and 3+; Instrument = ESI-TRAP. 
The proteins from the final report were checked by looking at the molecular weight and 
isoelectric pH (pI) calculated by the LC/MS-MS compared to the images of the 2D-gels. 
Only proteins showing good agreement with mass and pI on the 2D-gels were considered 
to be positive identifications (Fowler et al. 2008). In addition to this, the MOWSE scores 
(Pappin et al. 1993) were compared. Primarily one protein was chosen for each spot, but 
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in some cases there were several plausible hits. In those cases more than one protein was 
recognized as significant hits. In addition to using MASCOT, the proteins were also 
identified by using the database UniProt (www.uniprot.org). 
The chosen spots were analyzed further by LC-MS/MS, and the final report contained a 
list of proteins based on search on the database MASCOT 
(http://www.matrixscience.com).  
 
The first part of this search was done by Liz Stewart at Aberdeen Proteomics, Institute of 
Medical Science, University of Aberdeen. 
 
 
3.17 1D gels and Western blot 
The protein pools were electrophoresed in triplicates in a random order by adding 30µg 
protein/lane on 26-lane one-dimensional NuPage® Novex Midi Bis-Tris Gel under 
reducing conditions and transferred to immobilon-FL membrane. Odyssey® Two-Color 
Protein Molecular Weight Marker was electrophoresed in the first lane and after ten 
protein samples of every gel. After transfer, the membranes were treated with Odyssey 
Blocking Buffer diluted 1:1 with PBS buffer (for details, see Appendix 7) for one hour on 
rocker. The primary antibodies, StAR, vimentin, BAX, CYP17 and heat shock protein 70, 
were diluted in blocking buffer diluted 1:1 in PBST buffer (for details, see Appendix 7). 
Table 3.7 shows an overview over the dilutions of the antibodies and the manufactures. 
The membranes were incubated overnight on shaker in fridge. After the incubation 
period, the primary antibodies were collected and the membranes were washed 4 x5 
minutes at RT with PBST on rocker. The secondary antibodies, were diluted in Odyssey 
Blocking Buffer diluted 1:1 with PBST + 0.01% SDS. The membranes were incubated in 
60 minutes in RT on rocker. After incubation, the secondary antibodies were collected 
and the membranes were washed 4 x 5 minutes with PBST and 4 x 5 minutes with PBS.  
The protein bands were visualized by using an Odyssey infrared fluorescence imager. The 
electronic images were analyzed using Phoretic-1D Advanced software to determine band 
volumes and molecular weights.  
Both β-actin and α-tubulin were tested as loading controls. There were no large 
differences between β-actin and α-tubulin, and β-actin was chosen as a loading control. 
    
The volumes of β-actin were compared between the exposure groups for all the antibodies 
to validate the analysis.   
Each membrane was used for 2-3 antibodies using different channels to separate the 
fluorescent signals from the different antibodies. β-actin was added to all of the 
membranes, but due to the reuse of the membranes, not all of the pictures of the 
membranes presented in Results show β-actin. 
Table 3.7: The table shows information on the antibodies used in western blot, including dilutions, 
species molecular weight (kDa) and manufacturer. 
Antibody Dilution Species MW Manufacturer 
CYP17 1:5000 Rabbit 58 kDa  Peter O’Shaunessey 
BAX 1:200 Rabbit 23 kDa Santa Cruz Biotechnology, INC, UK 
HSP70 1:1000 Mouse 70 kDa abcam plc, Cambridge, UK 
StAR 1:500 Rabbit 30 kDa Douglas M. Stocco, Texas Tech University, Health Science Centre 
VIM 1:200 Mouse 58 kDa abcam plc, Cambridge, UK 
β actin 1:10000 Rabbit 42 kDa abcam plc, Cambridge, UK 
β actin 1:5000 Mouse 42 kDa abcam plc, Cambridge, UK 
 
All the data from the Western Blot were normalized by dividing the volumes on the 
loading control, β-actin.  
 
3.18 Statistics 
All the statistics were done by using JMP8 software. All the data sets were tested for 
normal distributing by using Shapiro-Wilk W test. This test has a null hypothesis that the 
samples come from a normally distributed population. If the calculated p-value is >0.05, 
the hypothesis is accepted and the samples are normally distributed. Next, the data sets 
were tested for homogenous variance. This was done by Levenes test. This test assesses 
the equality of the variance in the data sets by testing the means of each group of samples.  
Cells exposed to PFOS were compared to corresponding concentrations of the salt control 
TBA, while cells exposed to PFNA were compared to the solvent control, DMSO 0.1 %. 
In addition, the salt-control, TBA, was compared to the solvent control to exclude effects 
of the salt alone. 
P-values < 0.05 were considered significant. 
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3.18.1 Viability 
For cells exposed to PFOS, all the results from the Alamar Blue assay were both normally 
distributed and had a homogenous variance. Based on this significance was tested using 
ANOVA. The Tukey-Kramer honestly significant difference (HSD) test was used as a 
post-hoc test.  
The results from cells exposed to PFNA were not normally distributed, not even after log-
transformation. Due to this, Bartlett’s test was used to check the variance. The data set 
was homogenous according to this test, and the significance was tested by using 
Wilcoxon/Kruskal-Wallis Tests (rank sum).  
 
3.18.2 Endocrine effects – hormone quantification 
For cells exposed to PFOS, the concentrations of all the hormones were normally 
distributed and had homogenous variances. Based on this, significance was tested using 
ANOVA and the Tukey-Kramer honestly significant difference (HSD) test.  
For cells exposed to PFNA, oestradiol concentrations were both normally distributed and 
had equal variances. Hence ANOVA and the Tukey-Kramer HSD test were used to test 
significance.  
The testosterone concentrations were normally distributed after log-transformation and 
had a homogenous variance, and ANOVA and the Tukey-Kramer test was used to test 
differences compared to the control. Neither the progesterone concentrations nor the 
cortisol concentrations were normally distributed. Progesterone had a homogenous 
variance, while cortisol had a non-homogenous variance according to Bartlett’s test. Still, 
both progesterone and cortisol concentrations were tested for significance by using 
Wilcoxon/Kruskal-Wallis Test. Kruskal-Wallis test is used for data sets which are not 
normally distributed or have an equal variance, and the JMP8 Software combines 
Wilcoxon and Kruskal-Wallis into one test. 
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3.18.3 Proteins 
For cells exposed to PFOS, all the normalized volumes of the protein spots were both 
normally distributed and had equal variances. Hence, ANOVA and Tukey-Kramer Test 
were used to test significance. 
For cells exposed to PFNA, most of the normalized volumes for the protein spots were 
normally distributed and had an equal variance, and ANOVA and the Tukey-Kramer Test 
could be used to test significance. The normalized volumes of one of the spots (spot nr 
974) had to be log-transformed to become normally distributed and to get an equal 
variance. This spot was tested for significance by using ANOVA and Tukey-Kramer Test 
on the log-transformed data-set. For two of the spots (spot nr 853 and 1033), the 
normalized volumes were normally distributed after log-transformation, but did not have 
an equal variance. These were tested for significance by using Wilcoxon/Kruskal-Wallis 
Test. 
In addition, fold change values were calculated for each protein spot and each exposure to 
illustrate the exposure effects. This was done by dividing the normalized volumes from 
each spot on the corresponding control using an Excel sheet.  
 
3.18.4 Western blots 
For cells exposed to PFOS, all normalized volumes of the proteins (volume 
protein/volume loading control (β-actin)) were both normally distributed and had 
homogenous variances. Hence ANOVA and the Tukey-Kramer HSD Test were used to 
test significantly differences between the exposed cells and the control. 
For cells exposed to PFNA, all normalized volumes except CYP17, were normally 
distributed and had homogenous variances, and significance was tested by using ANOVA 
and Tukey-Kramer HSD Test. Normalized volumes of CYP17, were tested for 
significance by using Wilcoxon/Kruskal-Wallis Test. 
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4. Results 
4.1 Viability 
The cells exposed to PFOS had significantly lower viability compared to corresponding 
controls in all exposure doses, 150 µM, 175 µM and 200 µM (p=0.002, p=0.004 and 
p=0.0086 respectively) as shown in Fig 4.1. However the three concentrations were not 
significantly different from each other, and did not have a significant dose-response 
relationship. 
Cells exposed to all three doses of PFNA had no significant difference in viability 
compared to the control (Fig 4.2). All the exposure doses gave viability >90 %.  
 
Figure 4.1: The viability of H295R cells exposed to PFOS in three different doses; 150 µM, 175 µM and 
200 µM. The viability was measured by the alamarBlue® assay, and is illustrated as the % viability of 
the salt control, TBA, at corresponding concentrations. The boxes in the box plot contain the middle 
50 % of the data (25th-75th percentile). The line inside the boxes indicates the median, and the 
whiskers indicate the maximum and the minimum data value. *: Significantly different from TBA 
control within exposure group (P<0.05). The significance was tested by using Tukey-Kramer HSD 
test in JMP8 Software. 
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Figure 4.2: Viability of H295R cells exposed to three different doses of PFNA; 150 µM, 175 µM and 200 
µM. The viability was measured by the alamarBlue® assay, and is illustrated as % viability compared 
to the solvent control, DMSO 0.1 %. The boxes in the box plot contain the middle 50 % of the data 
(25th-75th percentile). The line inside the boxes indicates the median, and the whiskers indicate the 
maximum and the minimum data value. 
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4.2 Endocrine effects – hormone quantification 
4.2.1 Oestradiol 
The highest concentration of oestradiol in medium from PFOS exposed cells was found at 
the lowest exposure dose (150µM) at which the mean (SE) oestradiol concentrations were 
108 (8.9) pg/ml in exposed cells and 59 (7.7) pg/ml in TBA controls, respectively 
(P=0.0222; Fig 4.3). A significant negative dose-response relationship was found between 
PFOS exposure and oestradiol (p=0.0460) (Fig 4.3). 
Increasing dose of PFNA gave increasing concentrations of oestradiol, but the dose-
response was not significant (p=0.1278) (Fig 4.4).  
 
 
Figure 4.3: Oestradiol concentration measured in medium from H295R cells exposed to PFOS (yellow 
color) and in TBA controls (red color), both in three different exposure doses. TBA was used as a 
salt control for PFOS. The boxes in the box plot contain the middle 50 % of the data (25th-75th 
percentile). The line inside the boxes indicates the median, and the whiskers indicate the maximum 
and the minimum data value. *: Significantly different from TBA control within exposure group 
(P<0.05). The significance was tested Tukey-Kramer HSD test by using JMP8 Software. 
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Figure 4.4: Oestradiol concentration measured in medium from H295R cells exposed to three 
different doses of PFNA. DMSO 0.1 % was used as a solvent control (shown as 0 in the figure). The 
boxes in the box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the 
boxes indicates the median, and the whiskers indicate the maximum and the minimum data value. 
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4.2.2 Testosterone 
Increasing doses of both PFOS and PFNA were associated with a significant decrease in 
testosterone concentration. The dose-response relationship was significant for PFNA 
(p=0.0021), but not for PFOS (p=0.1030) with increasing dose. The reduction in the mean 
testosterone at the highest dose (200 µM) was 50% and 30% compared with controls for 
PFOS and PFNA exposed cells, respectively (Figs 4.5 and 4.6).   
 
 
Figure 4.5: Testosterone concentration measured in medium from H295R cells exposed to PFOS 
(yellow color) and in TBA controls (red color), both in three different exposure doses. TBA was used 
as a salt control for PFOS. The boxes in the box plot contain the middle 50 % of the data (25th-75th 
percentile). The line inside the boxes indicates the median, and the whiskers indicate the maximum 
and the minimum data value. *: Significantly different from TBA control within exposure group 
(P<0.05). The significance was tested with Tukey-Kramer HSD test by using JMP8 Software. 
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Figure 4.6: Testosterone concentration measured in medium from H295R cells exposed to three 
different doses of PFNA. DMSO 0.1 % was used as a solvent control (shown as 0 in the figure). The 
boxes in the box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the 
boxes indicates the median, and the whiskers indicate the maximum and the minimum data value. *: 
Significantly different from DMSO 0.1 % control within exposure group (P<0.05). The significance 
was tested with Tukey-Kramer HSD test by using JMP8 Software. 
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4.2.3 Progesterone 
Exposure with PFOS and PFNA both decreased production of progesterone. All exposure 
doses (150, 175 and 200 µM) differed significantly from controls (Figs 4.7 and 4.8). A 
significant negative dose response relationship was found for both compounds. The 
highest exposure doses of PFOS and PFNA caused a 50% and 75% reduction in mean 
progesterone concentration, respectively.   
 
 
Figure 4.7: Progesterone concentration measured in medium from H295R cells exposed to PFOS 
(yellow color) and in TBA controls (red color), both in three different exposure doses. TBA was used 
as a salt control for PFOS. The boxes in the box plot contain the middle 50 % of the data (25th-75th 
percentile). The line inside the boxes indicates the median, and the whiskers indicate the maximum 
and the minimum data value. *: Significantly different from TBA control within exposure group 
(P<0.05). The significance was tested with Tukey-Kramer HSD test by using JMP8 Software. 
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Figure 4.8: Progesterone concentration measured in medium from H295R cells exposed to three 
different doses of PFNA. DMSO 0.1 % was used as a solvent control (shown as 0 in the figure). The 
boxes in the box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the 
boxes indicates the median, and the whiskers indicate the maximum and the minimum data value. 
The two points over and under the box representing the solvent control, are outliers. *: Significantly 
different from DMSO 0.1 % control within exposure group (P<0.05). The significance was tested with 
Wilcoxon/Kruskal-Wallis test by using JMP8 Software. 
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4.2.4 Cortisol 
Exposure with PFOS and PFNA both caused a decrease in production of cortisol. All 
exposure doses (150, 175 and 200 µM) for cells exposed to PFOS and the two highest 
doses (175 and 200 µM) for cells exposed to PFNA differed significantly from their 
respective controls (Figs 4.9 and 4.10). A significant negative dose response relationship 
was found for both compounds. The highest exposure doses of PFOS and PFNA caused a 
70% reduction and 75% reduction in mean cortisol concentration, respectively.   
 
 
 
Figure 4.9: Cortisol concentration measured in medium from H295R cells exposed to PFOS (yellow 
color) and in TBA controls (red color), both in three different exposure doses. TBA was used as a 
salt control for PFOS. The boxes in the box plot contain the middle 50 % of the data (25th-75th 
percentile). The line inside the boxes indicates the median, and the whiskers indicate the maximum 
and the minimum data value. *: Significantly different from TBA control within exposure group 
(P<0.05). The significance was tested with Tukey-Kramer HSD test by using JMP8 Software. 
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Figure 4.10: Cortisol concentration measured in medium from H295R cells exposed to three different 
doses of PFNA. DMSO 0.1 % was as a solvent control (shown as 0 in the figure). The boxes in the 
box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates 
the median, and the whiskers indicate the maximum and the minimum data value. *: Significantly 
different from DMSO 0.1 % control within exposure group (P<0.05). The significance was tested 
Wilcoxon/Kruskal-Wallis test by using JMP8 Software. 
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4.3 Proteomics 
4.3.1 Proteomic profile 
The proteomic profile of the H295R cell line is shown in Fig. 4.11. The H295R cells gave 
a clean profile on the 2D-gels. Few of the gels had smears, and although some 
contamination of keratin, most likely from making the gels or handling the gels, the spots 
were clear with defined peaks. The Progenesis Samespots v3.3 defined 1409 spots. After 
checking each spot, 703 spots were included and 706 spots were excluded from the 
results. Of the 703 spots included in the results, 180 spot were statistically significant 
different between groups (p<0.05). Seventeen spots were excised to be further analyzed. 
An overview of the excised spots is shown in Fig 4.11 below.  
 
 
Figure 4.11: The proteomic profile of the H295R cell line. At the right in the figure, there is a 
molecular weight marker used to decide the molecular weight of the proteins. The pH ranges non-
linear from 3-10 from left to right. Each of the numbers, with belonging arrow, represents one spot 
that was excised and further analyzed.  
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4.3.2 Identified proteins 
The proteins that were identified and their level of expression (fold changes) are outlined 
in tables 4.1 and 4.2, respectively. Table 4.1 gives an overview over the proteins found 
and their functions and subcellular locations. Table 4.2 shows fold changes and p-values 
for the cells exposed to both concentrations of PFOS and PFNA, compared to their 
respective controls, TBA and DMSO. These fold changes were recalculated due to 
different controls used for PFOS and PFNA. 
Based on comparison of listed pI and mass for each protein and the gels, spot 897 
identified three proteins as possible hits and spot 644 identified two proteins as possible 
hits. For the rest of the spots, only the most probable proteins were taken in consideration. 
Spot 1323 and 1502 did not have any probable protein hits because neither of the hits 
matched the proteins mass and PI. These spots were probably contaminated and were 
excluded from the study. 
Several of the proteins identified were transcription factors involved in protein synthesis, 
such as eukaryotic translation initiation factor 3, eukaryotic translation elongation factor 2 
and eukaryotic initiation factor 4AII. In addition there was a structural protein, vimentin, 
a stress related protein, heat shock 70 kDa protein (HSP70) and a transport related 
protein, albumin, among the findings. All the proteins and their function are described in 
more detail in table 4.1
    
 
Table 4.1: Overview over the most significant protein findings in H295R cells exposed to PFOS and PFNA with TBA and DMSO 0.1 % as controls, respectively, 
identified by LC/MS-MS. The table gives information about each proteins mass (Da), isoelectric pH (PI), MOWSE score*, functions and subcellular location.  
Spot Protein Mass(Da) PI MOWSE score 
Gene 
Name Function 
Subcellular 
location 
Transport 
949 Albumin, isoform CRA_t 60211 6,66 111 ALB Transport Cytoplasm 
974 Serum albumin 71343 5,92 69 ALB Transport Cytoplasm 
Transcription/protein synthesis 
1033 Eukaryotic translation initiation factor 3, subunit M 42932 5,41 56 EIF3M Required for several steps in the initiation of the protein synthesis Cytoplasm 
897 Eukaryotic initiation factor 4AII 46593 5,33 241 EIF4A2 ATP dependent RNA helicase involved in cap recognition and required 
for mRNA binding to ribosome 
Cytoplasm 
501 Eukaryotic translation elongation factor 2 96246 6,41 700 EEF2 Promotes the GTP-dependent translocation of the nascent protein 
chain from  A-site to P-site of  ribosome 
Cytoplasm 
496 Eukaryotic translation elongation factor 2 96246 6,41 441 EEF2 Promotes the GTP-dependent translocation of the nascent protein 
chain from  A-site to P-site of  ribosome 
Cytoplasm 
EIF4A1- Eif4A: ATP-dependent RNA helicase. 953 Chain A, Chrystal structure of the Eif4a-Pdcd4 complex 44466 5,49 63 
DDX2A Pdcd4: Tumor suppressor, inhibits Eif4A 
Cytoplasm, 
Nucleus 
EIF4A1- Eif4A: ATP-dependent RNA helicase. 897 Chain A, Chrystal structure of the Eif4a-Pdcd4 complex 44466 5,49 293 
DDX2A Pdcd4: Tumor suppressor, inhibits Eif4A 
Cytoplasm, 
Nucleus 
1208 High mobility group protein B1 (HMGB1) 25148 5,76 177 FM1 Binds preferentially single-stranded DNA and unwinds double 
stranded DNA 
Nucleus 
523 unr protein (Cold shock domain-containing protein E1) 86599 6,17 161 CSDE1 DNA dependent regulation of transcription Cytoplasm 
897 Actin-like 6A isoform 1 47944 5,39 216 ACTL6A Involved in transcriptional activation and repression of select genes by 
chromatin remodeling 
Nucleus 
Stress 
644 Heat shock 70kDa protein 5 (HSP70) 72402 5,07 1015 HSPA5 Involved in folding and assembly of proteins in ER. May play a role in 
monitoring transport of proteins in the cell 
ER 
644 Protein disulfide isomerase A4 precursor 73229 4,96 725 PDIA4 Catalyzes the rearrangement of -S-S- bonds in proteins ER 
Structure 
972 Vimentin (vim) 53738 5,03 399 VIM Class-III intermediate filaments involved in cell motion and 
interspecies interaction between organisms 
Cytoplasm 
Lipid synthesis, gluconeogensis 
1277 Triosephosphate isomerase  26894 7,1 65 TPI1 Fatty acid biosynthesis, gluconeogenesis, glycolysis, lipid synthesis, 
pentose shunt 
Cytoplasm 
Cell cycle progression 
896 NEDD8-activating enzyme E1 catalytic subunit 52495 5,37 170 UBA3 Down-regulates steroid receptor activity. Necessary for cell cycle 
progression 
Nucleus 
Energy production 
853 ATP synthase, H+ transporting, mitochondrial F1 
complex, alpha subunit 1, cardiac muscle 
59785 9,07 1083 ATP5A1 Produces ATP from ADP 
Tumor modifier 
Mitochondria 
Purine salvage pathway 
1288 Phosphoribosyl transferase domain containing 1 66149 8,16 48 PRTFD
C1 
Purine ribonucleoside salvage, hypoxanthine 
phosphoribosyltransferase activity 
Cytoplasm 
*MOWSE-score in an algorithm described by (Pappin et al. 1993).
    
Table 4.2: Overview over fold change and p-values for all significant proteins findings for H295R 
cells exposed to PFOS and PFNA. Proteins from cells exposed to PFOS and PFNA have been 
compared to their respective controls, TBA and DMSO. P<0.05 are written in red. 
Protein Exposure Fold change P-value
PFOS 175 µM 2,3
PFOS 200 µM 2,4
PFNA 175 µM 1,9
PFNA 200 µM 2,4
PFOS 175 µM 2,3
Eukaryotic translation initiation PFOS 200 µM 1,3
factor 3, subunit M PFNA 175 µM -1,5 0,0833
PFNA 200 µM -2,1
PFOS 175 µM 1,8
PFOS 200 µM 1,2
PFNA 175 µM -1,1 0,7728
PFNA 200 µM -1,9
PFOS 175 µM 1,6
Phosphoribosyl transferase PFOS 200 µM 2,0
domain containing 1 PFNA 175 µM 1,7 0,0641
PFNA 200 µM 1,4
PFOS 175 µM -2,5
Eukaryotic translation PFOS 200 µM -3,1
elongation factor 2 PFNA 175 µM -1,2 0,1671
PFNA 200 µM -1,4
PFOS 175 µM -1,7
Eukaryotic translation PFOS 200 µM -2,0
elongation factor 2 PFNA 175 µM -1,1 0,3922
PFNA 200 µM -1,4
PFOS 175 µM -2,1
PFOS 200 µM -1,9
PFNA 175 µM -1,2 0,3153
PFNA 200 µM -1,9
PFOS 175 µM 2,0
Chain A, Chrystal structure of PFOS 200 µM 2,1
the Eif4a-Pdcd4 complex PFNA 175 µM 1,6 0,0942
PFNA 200 µM 1,5 0,1116
PFOS 175 µM 1,8
PFOS 200 µM 2,2
PFNA 175 µM 1,7
PFNA 200 µM 1,6
PFOS 175 µM -1,9
unr protein (Cold shock PFOS 200 µM -1,9
domain-containing protein E1) PFNA 175 µM -1,3
PFNA 200 µM -1,5
PFOS 175 µM 1,8
Chain A, Chrystal structure PFOS 200 µM 2,1
of the Eif4a-Pdcd4 complex PFNA 175 µM 2,2
PFNA 200 µM 1,7
PFOS 175 µM 1,8
Eukaryotic initiation PFOS 200 µM 2,1
factor 4AII PFNA 175 µM 2,2
PFNA 200 µM 1,7
Triosephosphate isomerase
HMG-1
Albumin, isoform CRA_t
Serum albumin
<0,0001
<0,0001
0,0005
0,0002
<0,0001
0,0037
0,0209
<0,0001
0,0266
0,0209
0,0029
0,0017
0,0324
<0,0001
0,0002
0,0409
<0,0001
0,0042
0,0358
0,002
0,0175
0,0188
0,0002
0,0003
0,0014
<0,0001
0,0081
0,0023
0,0035
0,006
0,0454
0,0134
0,0012
<0,0001
0,0016
0,0007
0,0012
<0,0001
0,0016
0,0007  
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Table 4.2 continues:  
Protein Exposure Fold change P-value
PFOS 175 µM 1,8
PFOS 200 µM 2,1
PFNA 175 µM 2,2
PFNA 200 µM 1,7
PFOS 175 µM 2,0
 NEDD8-activating PFOS 200 µM 2,1
enzyme E1 catalytic subunit PFNA 175 µM 1,8
PFNA 200 µM 1,7
PFOS 175 µM 1,7
PFOS 200 µM 1,2 0,2437
PFNA 175 µM 2,0
PFNA 200 µM 2,6
PFOS 175 µM 1,6
PFOS 200 µM 2,0 0,1597
PFNA 175 µM 1,2 0,29
PFNA 200 µM 1,3 0,1856
PFOS 175 µM 1,6
Protein disulfide isomerase PFOS 200 µM 2,0 0,1597
 A4 precursor PFNA 175 µM 1,2 0,29
PFNA 200 µM 1,3 0,1856
ATP synthase, H+ transporting, PFOS 175 µM 1,1 0,5011
 mitochondrial F1 complex, PFOS 200 µM 1,2 0,3634
alpha subunit 1, cardiac muscle PFNA 175 µM 1,2 0,2482
PFNA 200 µM -1,9
Actin-like 6A isoform 1
Vimentin
Heat shock 70kDa protein 5
0,0012
<0,0001
0,0016
0,0007
0,0012
0,0016
0,0127
0,0095
0,007
0,0045
<0,0001
0,0132
0,0132
0,0209  
 
4.3.3 TBA 
Out of seventeen excised spots, six were significantly different when TBA was compared 
to DMSO (Table 4.3). Two of these spots had no possible protein hits, and are not shown.  
Table 4.3: Overview over fold change and p-values for all significant proteins findings for H295R 
cells exposed TBA. The protein spots from the cells have been compared to DMSO 0.1 %. P<0.05 are 
written in red. 
Protein Exposure Fold change P-value
TBA 175 -1,3
TBA 200 -1,2
TBA 175 -1,1 0,7683
TBA 200 1,4
TBA 175 -1,1 0,5627
TBA 200 -1,4
TBA 175 -1,1 0,0664
TBA 200 -1,3
Albumin, isoform CRA_t
Serum albumin
HMG-1
Triosephosphate isomerase
0,0002
0,0071
0,0381
0,0492
0,0064  
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4.4 Western blots 
4.4.1 CYP17 
CYP17 was not significant differently expressed in PFOS exposed cell (Fig 4.13), or in 
PFNA exposed cells (Fig 4.14). A picture of the membrane is shown in Fig 4.12. 
 
CYP17
58 kDa
250 kDa
150 kDa
100 kDa
75 kDa
50 kDa
37 kDa
25 kDa
20 kDa
15 kDa
10 kDa  
Figure 4.12: Proteins pools from H295R cells exposed to PFOS and PFNA were electrophorized and 
transferred to a membrane, with TBA and DMSO 0.1 % as their respective controls. The membrane 
was coated with antibody against CYP17 (MW 58kDa), and thereby visualized, as seen in this figure. 
The protein pools from the cells were run as triplicates in a random order on the membrane. In 
addition a molecular weight marker was added in the first lane and in the middle lane, to determine 
the size of the antibody (MW listed to the left). The arrow at the right points at the bands used in 
statistics. 
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Figure 4.13: Average levels of CYP17 normalized with b-actin as loading control in H295R cells 
exposed to PFOS compared to corresponding concentrations of TBA.  The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. The red boxes 
represent cells exposed to TBA, while the yellow boxes represent cells exposed to PFOS. 
 
 
Figure 4.14: Average levels of CYP17 normalized with b-actin as loading control in H295R cells 
exposed to PFNA compared to DMSO 0.1 % (shown as 0 in the figure). The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. 
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4.4.2 BAX 
Exposure with PFOS (175 and 200 µM) caused a significant reduction in BAX expression 
compared with the controls, p=0.0091 and p=0.0074 respectively (Fig 4.16). PFNA 
exposure had no significant effect on BAX expression (Fig 4.17). A picture of the 
membrane is shown in Fig 4.15. 
 
B-actin
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BAX
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Figure 4.15: Proteins pools from H295R cells exposed to PFOS and PFNA were electrophorized and 
transferred to a membrane, with TBA and DMSO 0.1 % as their respective controls. The membrane 
was coated with antibody against BAX (MW 23 kDa) and the loading control, β-actin (42 kDa), and 
thereby visualized, as seen in this figure. The protein pools from the cells were run as triplicates in a 
random order on the membrane. In addition a molecular weight marker was added in the first lane 
and in the middle lane, to determine the size of the antibody (MW listed to the left). The arrows at the 
right point at the bands used in statistics. 
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Figure 4.16: Average levels of BAX normalized with b-actin as loading control in H295R cells 
exposed to PFOS compared to corresponding concentrations of the control TBA. The boxes in the 
box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates 
the median, and the whiskers indicate the maximum and the minimum data value. The red boxes 
represent cells exposed to TBA, and the red boxes represent cells exposed to PFOS. *: Significantly 
different from TBA control within exposure group (P<0.05). The significance was tested by using 
Tukey-Kramer HSD Test in JMP8 Software. 
 
 
Figure 4.17: Average levels of BAX normalized with b-actin as loading control in H295R cells 
exposed to PFNA compared to DMSO 0.1 % (shown as 0 in the figure). The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. 
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4.4.3 VIM 
Exposure to PFNA gave a significant increase in vimentin expression compared to 
DMSO 0.1 % in the highest exposure dose (p=0.0031), and a borderline significant 
increase in 175 µM (p=0.0990) as shown in the figure below (Fig 4.20). PFOS exposure 
was not significant different from the corresponding concentrations of TBA (Fig 4.19). A 
picture of the membrane is shown in Fig 4.18. 
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Figure 4.18: Proteins pools from H295R cells exposed to PFOS and PFNA were electrophorized and 
transferred to a membrane, with TBA and DMSO 0.1 % as their respective controls. The membrane 
was coated with antibody against VIM (MW 58 kDa), and thereby visualized, as seen in this figure. 
The protein pools from the cells were run as triplicates in a random order on the membrane. In 
addition a molecular weight marker was added in the first lane and in the middle lane, to determine 
the size of the antibody (MW listed to the left). The arrow at the right points at the bands used in 
statistics. 
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Figure 4.19: Average levels of VIM normalized with b-actin as loading control in H295R cells exposed 
to PFOS compared to corresponding concentrations of the control TBA. The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. The red boxes 
represent cells exposed to TBA, and the yellow boxes represent cells exposed to PFOS. 
 
 
Figure 4.20: Average levels of VIM normalized with b-actin as loading control in H295R cells exposed 
to PFNA compared to DMSO 0.1 %. The boxes in the box plot contain the middle 50 % of the data 
(25th-75th percentile). The line inside the boxes indicates the median, and the whiskers indicate the 
maximum and the minimum data value. *: Significantly different from DMSO 0.1 % control within 
exposure group (P<0.05). The significance was tested by using Tukey-Kramer HSD Test in JMP8 
Software. 
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4.4.4 StAR 
None of the exposures showed any significant differences to their respective controls in 
the expression of StAR, as shown in the figures below (Figs 4.22 and 4.23). A picture of 
the membrane is shown in Fig 4.21. 
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Figure 4.21: Proteins pools from H295R cells exposed to PFOS and PFNA were electrophorized and 
transferred to a membrane, with TBA and DMSO 0.1 % as their respective controls. The membrane 
was coated with antibody against StAR (MW 30 kDa), and thereby visualized, as seen in this figure. 
The protein pools from the cells were run as triplicates in a random order on the membrane. In 
addition a molecular weight marker was added in the first lane and in the middle lane, to determine 
the size of the antibody (MW listed to the left). The arrow at the right points at the bands used in 
statistics. 
 
 
 
 
88 
    
 
Figure 4.22: Average levels of VIM normalized with b-actin as loading control in H295R cells exposed 
to PFOS compared to corresponding concentrations of the control TBA. The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. The red boxes 
represent cells exposed to TBA, while the yellow boxes represent cells exposed to PFOS. 
 
 
Figure 4.23: Average levels of StAR normalized with b-actin as loading control in H295R cells 
exposed to PFNA compared to DMSO 0.1 % (shown as 0 in the figure). The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. 
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4.4.5 HSP70 
Exposure to PFOS and PFNA did not give any significant differences in expression of 
HSP70, as shown in the figures below (Figs 4.25 and 4.26). However exposure to TBA 
175 µM gave a statistically significant decrease in HSP70 expression compared to DMSO 
(p=0.0262) (Fig 4.25). A picture of the membrane is shown in Fig 4.24. 
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Figure 4.24: Proteins pools from H295R cells exposed to PFOS and PFNA were electrophorized and 
transferred to a membrane, with TBA and DMSO 0.1 % as their respective controls. The membrane 
was coated with antibody against HSP70 (MW 70 kDa), and thereby visualized, as seen in this figure. 
The protein pools from the cells were run as triplicates in a random order on the membrane. In 
addition a molecular weight marker was added in the first lane and in the middle lane, to determine 
the size of the antibody (MW listed to the left). The arrow at the right points at the bands used in 
statistics. 
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Figure 4.25: Average levels of HSP70 normalized with b-actin as loading control in H295R cells 
exposed to PFOS compared to corresponding concentrations of the control TBA. The boxes in the 
box plot contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates 
the median, and the whiskers indicate the maximum and the minimum data value. The red boxes 
represent cells exposed to TBA, while the yellow boxes represent cells exposed to PFOS. 
 
 
Figure 4.26: Average levels of HSP70 normalized with b-actin as loading control in H295R cells 
exposed to PFNA compared to DMSO 0.1 % (shown as 0 in the figure). The boxes in the box plot 
contain the middle 50 % of the data (25th-75th percentile). The line inside the boxes indicates the 
median, and the whiskers indicate the maximum and the minimum data value. 
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5. Discussion 
To my knowledge, this is the first exposure study investigating both endocrine effects and 
alterations in protein expression in the H295R cell-line after exposure to PFOS and 
PFNA.  
In the present study significant effects of PFOS and PFNA on adrenal steroidogenesis and 
protein expression were found. The general pattern of steroid response with the two 
compounds was a decrease in hormone secretion. PFOS proved to be cytotoxic, but the 
cytotoxicity was not dose dependent. 
Allthough the mechanisms as to which PFCs alter cell functions in adrenal cells are not 
known, the current study provided new knowledge on how these compounds affected 
protein expression and might contribute to a better understanding of mechanisms related 
to PFC exposure. 
The occurrence of PFCs in the environment has been reported to vary greatly, with 
highest levels around industrial areas. The highest levels of PFC has been found in mice 
inhabiting areas around a fluorotelomer plant in Belgium (180 000 ng/g). In invertebrates, 
fish and humans the highest levels reported are 2-280 ng/g, 3250 ng/g and 73 ng/ml 
respectively (Houde et al. 2006). The exposure doses used in this study were far higher 
compared to natural occurring levels of PFCs. However, due to accumulation of PFCs in 
protein-rich tissues and slow elimination rate of PFCs, there might be higher doses found 
naturally in target organs in organisms than reported.  
 
5.1 Viability 
The viability for H295R cells exposed to PFOS was decreased in all the three doses 
although there was no significant dose response relationship. Since all the doses gave 
significantly lower viability, the doses used for PFOS seem to have a cytotoxic effect and 
lower doses should have been tested. The decreased viability must be considered for the 
other results. However, significant dose-response relationships at hormone levels (this 
will be discussed later) indicated that other endpoint analyses were not influenced by the 
reduced viability. 
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The cells exposed to PFOS, were also exposed to TBA since the PFOS came as a 
tetrabutylammonium-salt. This may affect the cells, although there was no decrease in 
viability in cells exposed only to TBA dissolved in DMSO. TBA is a non-selective 
potassium channel blocker which may change the membrane potential (Sohn et al. 2000). 
In a study on human endothelial cells, the viability of cells exposed to TBA was not 
changed compared to controls  (Krötz et al. 2002) as seen in this study. PFOS have been 
found to increase the permeability for other compounds in fish leukocytes while being 
inactive itself (Hu et al. 2003). Due to the previous findings there was reason to believe 
that the alterations in viability may partly be caused by the combination of PFOS and 
TBA. 
Decreased cell viability in tilapia hepatocytes exposed to PFOS has been reported (Liu et 
al. 2007b). A possible explanation was suggested to be oxidative stress caused by PFOS 
and thereby production of ROS. For the current study, proteins found regulated as a 
response to PFCs indicate that oxidative stress occurs in the cells (this will be discussed 
later). A future perspective would be if oxidative damage might be an explanation for the 
decreased viability. Viability was not affected in hepatocytes from Atlantic salmon 
exposed to PFOS (Krøvel et al. 2008), and this illustrates that there is interspecies 
variation in the response to PFOS.  
In the current study, the viability of H295R cells exposed to PFNA was not altered. In 
contrary, PFNA has been found to cause apoptosis in rat spleen in a previous study, 
where the apoptosis was suggested to be related to oxidative stress and mitochondria 
independent of caspase death signal pathway (Fang et al. 2010).  
 
5.2 Endocrine effects – hormone quantification 
All the measured hormones were altered after exposure to PFOS or PFNA. PFOS has 
been reported to stimulate the steroid production at lower exposure doses, and inhibit the 
production at higher exposure doses. The stimulatory effect was suggested to be caused 
either by stimulatory effects of ROS or inhibition in steroid clearance mechanisms (Oakes 
et al. 2005). The inhibition of steroid production might cause reduced cholesterol or 
reduced transport of cholesterol to the mitochondria for conversion to steroid hormones 
(Oakes et al. 2005). 
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5.2.1 Oestradiol 
The increased production of oestradiol found in the cells exposed to PFOS revealed a 
tendency of a negative dose-response. Since the viability did not have the same negative 
dose-response relationship, the increase in oestradiol levels at the lowest exposure dose 
(150 µM) cannot be explained by a change in viability. 
Several previous studies have shown increased oestradiol levels induced by perfluorinated 
compounds (Biegel et al. 1995; Liu et al. 2007a) as seen in this study. 
An unpublished study (Kraugerud et. al 2010, manuscript in preparation), showed 
increased oestradiol levels in the same cell system as used in this study (H295R). 
However this study used other concentrations and another exposure design – the cells 
were exposed in 24 well plates as opposed to exposure in 75 cm2 tissue culture flasks in 
this study. The concentrations of PFOS and PFNA in the previous study ranged from 6 
nM to 600 µM. When recalculating the amount of compound per cell, the doses used in 
the current study were nearly equivalent to the next highest exposure dose (60 µM) in the 
previous study (see Table 3.1 in Material and Methods). However the increased levels of 
oestradiol at the lowest exposure dose in the current study (150 µM) do not correspond to 
the previous study in which the increase was found at the highest dose, not at the next 
highest dose. The fact that different results were obtained with the same cell line using 
different exposure design can indicate that this in vitro cell assay is sensitive to small 
changes. This might also be caused by different operators when conducting the study. 
 
5.2.2 Testosterone 
Cells exposed to PFOS and PFNA gave significant decreased secretion of testosterone. 
This correlates with previous in vitro studies done in Leydig cells exposed to PFOA 
(Biegel et al. 1995) and in testes from rats exposed to perfluorododecanoic acid (PFDoA) 
(Shi et al. 2007) where the levels of testosterone were significantly decreased.  
Previous in vivo studies have also reported decreased levels of testosterone in rats 
exposed to PFNA (Feng et al. 2009) and decreased levels in testosterone in PFOA 
exposed rats corresponding to the observed decreases in testosterone in the current study 
(Biegel et al. 1995). 
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There was a trend in the data that testosterone decreased in a non-linear pattern with 
increasing concentrations of PFNA. This would agree with a previous report claiming that 
PFCs have nonlinear pharmacokinetics (Andersen et al. 2008) 
 
5.2.3 Progesterone 
Changes in progesterone levels as a consequence of exposure to PFOS or PFNA have to 
my knowledge not been reported in previous studies. However, a study done in testis 
from rats exposed to PFDoA, reported decreased serum progesterone levels (Shi et al. 
2010). This corresponds to the results in the current study. In addition, a study done in 
rats, the corticosterone levels in PFOS exposed animals were increased (Austin et al. 
2003). Another study reported decreased levels of corticosteroids in mice (Ribes et al. 
2010). Several studies show decreased levels of cholesterol in different species, such as 
humans, monkeys, rats, mice and birds (Berthiaume et al. 2002; Hoff et al. 2005; Lin et 
al. 2009; Seacat et al. 2002). This indicates that the effects of PFOS and PFNA (due to 
similar modes of action) may affect mineralcorticoids both up-stream and down-stream of 
progesterone. However, the studies were done in vivo and the results cannot directly be 
compared to in vitro studies using a cell-line representing only one element of the HPA-
axis, as in the current study.  
 
5.2.4 Cortisol 
Increase in cortisol levels due to exposure of PFCs have been reported in a study done in 
mice exposed to PFNA (Fang et al. 2008). In contrast to that report, the current study 
showed decreased cortisol levels. However, the previous study was done in vivo and 
reported increased ACTH levels in addition to the increased cortisol levels, and cannot be 
directly compared to the current study.  
 
5.3 Protein profile 
The H295R cells gave a clean profile on the 2D-gels. Few of the gels had smears, and 
although some contamination of keratin, most likely from making the gels or handling the 
gels, the spots were clear with defined peaks. This suggests that the H295R cell-line is 
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suitable for investigation of protein expression. There is only one previous study using 
H295R cells to investigate protein expression. The effects of mitotane on growth, 
steroidogenesis and proteomic profile were described, and the proteome profiling allowed 
identification of proteins related to different cellular function (Stigliano et al. 2008).  
One study has investigated protein expression after exposure to PFCs. For zebra fish 
embryos exposed to PFOS, the proteomic profile included proteins involved in energy 
metabolism, cholesterol, oxidative stress, and membrane integrity (Shi et al. 2009). 
Compared to the current study, only one of the proteins was in the same family in the two 
studies; eukaryotic translation elongation factor 2 (current study) and eukaryotic 
translation elongation factor 1 (zebra fish study). These proteins will be further described 
later. 
 
5.4 Identified proteins 
Allthough the viability was decreased for cells exposed to PFOS, the same amount of 
proteins were added to the gels (800 µg). Thus the proteins identified have been regarded 
as truly regulated. 
The proteomic profile from this study included proteins involved in several cellular 
processes which can be divided into different categories. Out of the 18 identified proteins 
found regulated, 3 proteins occurred in more than one spot (albumin, eEF2 and eIF4A1-
Pdcd4 complex). That gave a total of 15 identified proteins found regulated. Out of the 15 
identified proteins, at least 7 were found to be involved in transcription/protein synthesis, 
at least 3 were found to be involved in stress response, and at least 6 were found to be 
involved in carcinogenesis. There are limited informations about some of the proteins in 
response to exposure, and the mechanisms of action are not known. Thus discussing the 
regulated proteins was complicated and difficult.  
 
5.4.1 Transport proteins 
The increased levels of serum albumin found in the H295R cells exposed to PFOS and 
PFNA might be connected with PFCs affinity for binding to proteins. Albumin is a 
transport protein found in high concentrations in blood plasma, providing the cells with 
inorganic ions, amino acids, fatty acids etc. A previous study reported that PFOS 
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primarily binds to serum albumin in several organisms, thereby reducing the effects of the 
compound (Jones et al. 2003). Another report demonstrated an interaction between PFOA 
and serum albumin (Wu et al. 2009). Considering the chemical structure of PFCs, it is 
likely that PFNA also binds to albumin. It is unclear how the increased serum albumin in 
the current study can be explained, since it is not known that synthesis of this protein 
takes place in H295R cells. There was some serum albumin in the cell culture medium, 
but the increased albumin was measured from the cells, and not the medium. In addition, 
the increase was significant compared to the control. The strong binding of PFCs to 
serum albumin would logically result in decreased albumin levels in the cells, but instead 
elevated albumin levels were found in all the exposed cells except for one albumin 
isomere from cells exposed to PFNA. A reason for the increased serum albumin in cells 
exposed to PFOS might have been the capability of PFOS to increase the permeability for 
other compounds (Hu et al. 2003) and thereby caused a leakage of albumin from the cell 
culture medium into the cells. 
 
5.4.2 Proteins involved in transcription/protein synthesis 
In the current study high mobility group protein B1 (HMGB1) was decreased in cells 
exposed to both PFOS and PFNA. High mobility group proteins (HMG) are among the 
most ubiquitous, abundant and evolutionary conserved protein in eukaryotes. HMG 
proteins are divided into three different families; HMGA, HMGB and HMGN. HMGB1/2 
are cytoplasmic proteins with the ability to migrate between the cytoplasm and nucleus 
dependent on cell-cycle. The roles of HMGB have been found to be involved both in 
DNA binding, promoting the transcription of several genes, and as cytokines and/or 
growth factors. HMGB1 establish protein-protein interactions with specific transcription 
factors, including all steroid nuclear receptors, enhances transcription from steroid 
receptor response elements by bending the DNA. HMGB1 is found to activate the NF-KB 
signaling pathway, and be involved in the recognition of distorted and damaged DNA 
structures, in maintenance of genome integrity, and in DNA repair (Bianchi et al. 2005; 
Czura et al. 2001). In addition HMGB1 has been found to increase the transcription when 
interacting with steroid hormone receptors (Thomas et al. 2001). Several studies have 
suggested that overexpression of HMGB is involved in development of cancer (Lange et 
al. 2009; Roesli et al. 2009). The decreased levels of HMGB1 in the exposed cells in the 
current study might partly be explained by the reports of increased release of HMGB1 
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into the extracellular medium by apoptotic and autophagic cells in response to stress or 
necrosis, to alert other cells about danger (Tang et al. 2010). Decreased viability in 
response to PFOS exposure might partly be explained by the down-regulation of 
HMGB1, since down-regulation of HMGB1 in prostate cancer cells has been reported to 
result in apoptosis (Tang et al. 2010). A future perspective would be to measure the levels 
of HMGB1 in the growth medium from the exposed cells.  
The eIF4A-Pdcd4 complex was up-regulated in both cells exposed to PFOS and PFNA in 
the current study. Pdcd4 has been identified as a tumor suppressor shown to suppress 
neoplastic transformation and tumor phenotype. eIF4A functions as an ATP-dependent 
RNA helicase to catalyze unwinding of mRNA secondary structure. It mediates binding 
of mRNA to the 40S subunit of the ribosome (Quinn et al. 1999). The interaction between 
Pdcd4 and eIF4A inactivated the helicase function of eIF4A, suppresses cap-dependent 
translation and inhibits the activator protein 1 (AP-1) transactivation (Loh et al. 2009). 
The up-regulation of this complex suggests an increased inhibition of transcription 
through AP-1. 
Eukaryotic initiation factor 4A2 (eIF4A2) were found to be increased in both cells 
exposed to PFOS and PFNA in the present study. eIF4A2 is one of three isoforms of 
eIF4A found in mammals (Li et al. 1999). It has shown to be down-regulated by high 
glucose levels in rat β-cells. This suggests that eIF4A2 may contribute to regulation of 
insulin production in response to glucose and thus may have a role in glucose homeostasis 
(Cheyssac et al. 2006). In addition, eIF4A2 has found to be a putative contributor to type 
2 diabetes in presence of metabolic stress (Cheyssac et al. 2006). The up-regulation of 
this protein indicated an increased transcription.  
In the present study, levels of eukaryotic initiation elongation factor 2 (eEF2) were found 
to be down-regulated in both cells exposed to PFOS and PFNA. eEF2 promotes the GTP-
dependent translocation of the nascent protein chain from the A-site to the P-site of the 
ribosome (Ortiz et al. 2006). The down-regulation of eEF2 might be caused by 
phosphorylation and inactivation due cellular stress (Kang et al. 2007). In the current 
study eEF2 were found as two isomers. This suggests that the protein might have been 
post-translational altered (Kang et al. 2007).  
The levels of eukaryotic initiation factor 3 subunit M (eIF3M) were increased in cells 
exposed to PFOS, and decreased in cells exposed to PFNA. Eukaryotic initiation factor 3 
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(eIF3) is a complex initiation factor that plays at least two roles in the protein synthesis; 
eIF3 binds to the 40S ribosome and facilitate binding of Met-tRNA/eIF2 complex to form 
the preinitiation complex, and secondly eIF3 assists eIF4 in recruiting mRNA to the 
ribosome (Zhou et al. 2005). Correlation between abnormal levels of eIF3 subunits and 
cancer suggest that regulation of eIF3 might be important in determining the balance 
between cell proliferation and apoptosis (Zhang et al. 2007). This correlated with the 
increased levels of eIF3M and the decreased viability in cells exposed to PFOS seen in 
this study. 
In the current study, decreased levels of the protein upstream of N-ras (unr protein) were 
found in both cells exposed to PFOS and PFNA. The unr protein contains several cold 
shock domains (CSD) and are mainly found either in soluble form or associated to 
membranes, mainly ER, in the cytosol. They act as translational regulators and are 
involved in mRNA stability. The CSD of unr functions in binding proteins and nucleic 
acid, and show preference for unstructured single stranded DNA and RNA. It has been 
found to be essential due to a study where unr-deficient mice died at about 10 days of 
embryonic development (Mihailovich et al. 2010). The down-regulation of unr protein 
might be reflected in the reduced transcription factors found in the current study, as the 
unr proteins may act as translational regulators and are found to be involved in mRNA 
stability. 
The actin-like 6A isoform 1 (ACTL6A) levels were increased in both cells exposed to 
PFOS and PFNA in the current study. ACTL6A belongs to a family of actin-related 
proteins and is associated with chromatin and involved in transcriptional regulation by 
establishment, remodeling and maintenance of chromatin structure (Harata et al. 1999). 
The increased protein expression of ACTL6A may suggest the increased need of 
chromatin remodeling as a response to exposure. 
The down-regulation of some of the transcription factors may be the cells response to 
stress and repair mechanisms caused by the exposure. The transcription factors did not 
give information about which genes that may be down-regulated, only that there was a 
response in the cells. A reason for the down-regulation might have been the need of 
energy for other processes in the cell to deal with stress. RNA have been isolated from the 
cells, and as a further perspective, it would be interesting to see which genes are regulated 
after exposure of PFOS and PFNA.  
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Previous research has reported PFCs as peroxisome proliferating compounds as as 
agonists of PPAR which may cause a DNA binding-independent interference of 
transcription factors (Fang et al. 2008). This might be reflected in the decreased 
expression of transcription factors reported in the current study. 
 
5.4.3 Structural proteins 
In the current study, levels of vimentin were increased in both cells exposed to PFOS and 
PFNA. Vimentin is a structural protein in the class of intermediate filaments of the cell. 
The filaments are associated with both the plasma and the nuclear membrane (Ferrari et 
al. 1986). Lipid droplets in adrenal cells are attached to vimentin. Alterations in vimentin 
might affect cells by decreasing the efficiency of some transport processes. Vimentin 
might bind proteins that play a role in the intracellular transport of lipids (Gillard et al. 
1998).  
Vimentin is related to oxidative stress by alternation in cytoskeleton organization and 
induction of cytotoxicity (Hung et al. 2009), and is found to be a major molecule initiated 
and promoted by persistent oxidative stress (Tsubota et al. 2010). The increased vimentin 
in the current study might have been a response to oxidative stress. 
 
5.4.4 Stress related proteins 
Several studies have reported oxidative stress in response to exposure of PFCs (Fang et 
al. 2010; Liu et al. 2007b; Oakes et al. 2005). The heat shock protein HSP70 was 
increased in both cells exposed to PFOS and PFNA. Heat shock proteins are involved in 
the folding and assembly of proteins in ER, and might play a role in monitoring the 
transport of proteins through the cell. They have been found to have a protective role 
during cellular stress. Some of the functional properties are folding of proteins, 
maintenance of proteins in native folded states and repair of promotion of the degradation 
of misfolded proteins. In addition, the heat shock proteins modulate the progression 
and/or engagement of apoptosis (Huang et al. 2001). This might have had an effect on the 
viability for cells exposed to PFOS as the fold change was high for both concentrations 
(fold change =1.6 and 2.0). 
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Mice exposed to thermal stress resulted in rapid induction and expression of HSP70, 
especially in organs not constitutively expressing HSP70, including the liver, pancreas, 
heart, lung, adrenal cortex and intestine (Huang et al. 2001). Gene expression studies in 
Atlantic salmon hepatocytes exposed to PFOS have shown enhanced cellular stress. The 
mechanism is not known, but HSP70 gene expression was elevated (Krøvel et al. 2008) as 
in the present study.  
HSP70 and vimentin is reported to interact and colocalize in response to stress (Evans 
1998), and this correlates with increased levels of both HSP70 and vimentin in the current 
study. 
The levels of protein disulfide isomerase A4 (PDIA4) were increased in both cells 
exposed to PFOS and PFNA in the current study. PDI is a family of proteins which 
functions as chaperones that catalyzes thiol sulfide exchange, mainly in the ER, to ensure 
the correct folding of nascent proteins (Stockwin et al. 2007). The proteins of the PDI 
family are found to bind specifically to DNA sequences, encoding DNA repair proteins. 
This suggests that they play a role in regulating stress response genes (Huang et al. 2009). 
A gene expression study done in hepatocytes from Atlantic salmon suggests that PDI 
plays an important protective role in cellular stress response to PFOS, in addition to its 
isomerase activities (Huang et al. 2009). This correlates with the increased fold changes 
(1.6 and 2.0) of PDIA4 seen after exposure of PFOS of the H295R cells in this study. The 
up-regulation of PDIA4 might be associated with increased ACTL6A due to the DNA 
repair capabilities of PDIA4 and ACTL6A capabilities of remodeling chromatin structure 
(Harata et al. 1999). In addition PDI has been reported to be one of the key elements in 
development of human lung cancer (Bührens et al. 2009). 
 
5.4.5 Lipid synthesis 
In the current study, triosephosphate isomerase (TPI) was increased both in cells exposed 
to PFOS and PFNA. TPI is an enzyme that catalyzes the conversion of dehydroxyacetone 
phosphate and glyceraldehyd 3-phosphate in the gluconeogenesis and glycolysis pathway. 
It is also important in the synthesis of fatty acids and the penthose-phosphate shunt, 
where glucose is oxidized coupled to the NADPH synthesis. The TPI gene is 
characterized as a housekeeping gene because the expression of the gene is found in all 
cell types, and is found to be required for cell growth and maintenance (Brown et al. 
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1985). Due to the involvement in the glucolytic pathway, the increase of TPI in the 
current study may be related to requirement of energy due to increased stress in the 
exposed cells (Di Michele et al. 2010).  TPI has been reported to play a role in pathology 
of human cancer (Bührens et al. 2009; Di Michele et al. 2010; Roth et al. 2010).  
 
5.4.6 Cell cycle progression 
In the current study, the NEDD8 activating enzyme E1 was found to be up-regulated in 
both cells exposed to PFOS and PFNA. NEDD8 is an ubiquitin-like molecule, and has 
been found to be essential both mitotic and endoreduplicative cell cycle progression. It is 
essential for regulation of protein degradation pathways involved in cell cycle progression 
and morphogenesis (Tateishi et al. 2001).  
The enzymes responsible for conjugating ubiquitin into substrates can be divided into 
three classes; ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2) and 
ubiquitin-protein ligases (E3) (Liakopoulos et al. 1998). In previous reports, it has been 
suggested that the ubiquitin-proteasome pathway may play an important role in regulation 
of nuclear receptors levels and restricting the duration and magnitude of receptor activity 
in response to hormones. Uba3 is the catalytic subunit of NEDD8 activating enzyme, and 
is found to significantly repress reporter gene expression mediated by steroid receptors. 
Uba3 does not interfere with the initiation of receptor-mediated transcription activity, but 
it is suggested to suppress the steroid receptor activity by promotion the termination of 
receptor-mediated gene transcription (Fan et al. 2002). This is interesting because of the 
decreased secreted levels of hormones measured in medium from the exposed cells in this 
study. 
 
5.4.7 Energy production  
There was an increase in ATP synthase, H+ transporting, mitochondrial F1 complex, 
alpha subunit isoform a (ATP5A1) in cells exposed to PFOS and the middle dose of 
PFNA (175 µM), while the highest dose of PFNA caused a decreased level of the protein 
in the cells. ATP5A1 encodes a subunit of mitochondrial ATP synthase. ATP synthase 
catalyzes the synthesis of ATP to ADP. ATP5A1 is a putative modifier gene which 
regulates tumor development. Absence of ATP5A1 leads to apoptosis of the cell (Seth et 
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al. 2009). The increased need of energy due to stress might explaine the increased levels 
of ATP5A1 in the present study. 
 
5.4.8 Purine salvage pathway 
The levels of phosphoribosyl transferase domain containing 1 (Prtfdc1) were increased in 
both cells exposed to PFOS and PFNA. Prtfdc1 is a protein that is involved in the purine 
salvage pathway in which produces purine nucleosides from derivates without de novo 
synthesis. Disorder in the purine metabolism can lead to immunodeficiency (Nyhan 
2005). The increase of Prtfdc1 in the current study might be due to increased DNA repair 
as a response to stress. 
 
5.4.9 Protein expression compared to gene expression 
Gene expression studies have reported various changes in different organisms; salmon 
hepatocytes exposed to PFOS gave changed expression in genes included in stress, 
apoptosis and lipid metabolism (Krøvel et al. 2008), livers from PFOS exposed rats 
showed altered metabolic status (Bjork et al. 2008), PFOS exposed skin cells from 
dolphins altered genes involved in cellular stress response, cell cycle progression and 
proliferation, and protein translation (Mollenhauer et al. 2009), and chickens exposed to 
PFOS and PFOA altered genes involved in transport of electrons and oxygen, metabolism 
of lipids and fatty acids and protein amino acid phosphorylation and proteolysis (Yeung 
et al. 2007). These gene expression studies correlate with the current study when 
comparing the genes and the proteins. The genes found in the previous studies and the 
proteins found in this study were not the same, but they have similar functions such as 
lipid metabolism, apoptosis, cellular stress response and transcription. 
After proteomic analysis, none of the key-enzymes included in the steroidogenesis were 
found to be affected by exposure to PFOS or PFNA. In a gene expression study, HMGR 
was reported down-regulated in H295R cells exposed to PFNA (Kraugerud et. al 2010, 
manuscript in preparation). However, only 17 of the 180 significant spots in the current 
study were identified. There might still have been regulations in proteins involved in 
steroidogenesis. If the RNA had been measured either by q-PCR or microarrays, it is 
possible that some of the key-enzymes in the steroidogenesis would be found up- or 
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down-regulated. Another possible explanation might have been a delayed response. A 
further perspective is to expose the cells the same way as in this study, but delay the 
isolation of proteins. This may result in more representative proteins being regulated in 
the response to exposure.  
 
5.5 IPA network 
In order to increase the understanding of the results of the proteomic analysis, it is 
important to understand the interactions between proteins. One way of doing this is to use 
network programs. These programs make networks based on their known interactions. 
Ingenuity Pathway Analysis Software (IPA) is one program used in making networks. 
This software defines functional networks based on the gene names of the proteins, and 
does not consider the origin of the tissue. Still, the network made by IPA gives an 
illustration of the interactions between the proteins found in this study. Thus the use of 
this program will be discussed instead of considered as a result. 
 
Figure 5.1: This figure is an illustration of the relation between the proteins found up- or down-
regulated after proteomic analysis; 2D-gel and LC-MS/MS, of protein isolated from H295R cells 
exposed to PFOS and PFNA. This network was made by Ingenuity Pathway Analysis (IPA) by 
inserting the gene names of the detected proteins. The green symbols represent down-regulation, 
while the red symbols represent up-regulation. The white symbols represent proteins added by the 
software. Classifications of the proteins are explained in the blue box at the right. 
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Figure 5.1 shows a functional network identified by IPA. Proteins isolated from cells 
exposed to PFNA 200 µM were used to generate this network, but similar networks were 
identified for all exposures used, only with few differences in fold change. The relations 
between proteins are independent of up- or down-regulation of protein synthesis.  
Interestingly nearly all of the proteins found regulated were connected in the same 
network (~95 %). Originally IPA made two separate networks, but due to similarities in 
functions, a merge of the networks was possible. The top part of the network, with beta-
estradiol and insulin in central positions, was defined by IPA to be involved in cancer, 
cell-to-cell signaling and interaction, and tissue development. The lower part was defined 
to be involved in protein synthesis, gene expression and RNA trafficking.  
The functions of the proteins found regulated in this study (colored red or green in figure) 
have been described above. For the genes found connected to the genes of the protein 
products in the lower network (labeled white), eIF3A is a translation initiation factor in 
the same family as eIF3M, and eIF4G1 is in the same family as eIF4A, eIF4A1, eIF4A2 
and eIF4F, as described earlier. Poly (A) binding protein (PABP) is a cytosolic protein 
found to be ubiquitous and abundant. It is involved in mRNA translation by mediate 
mRNA circularization through binding of the eIF4F translation initiation complex which 
enhances translation by facilitating recycling of ribosomes. In addition PABP recruits 
various translation factors to the translating mRNA, and partners with the eukaryotic 
release factor eRE3 (Kozlov et al. 2001).  
The top part of the network generated by IPA, representing genes involved in more 
general responses within the cell, have beta-estradiol in one of the central positions. This 
is interesting considering the H295R cells ability to perform full steroidogenesis. As 
mentioned above, oeastradiol measured in the medium collected from the exposed cells 
was increased, significantly in cells exposed to PFOS and borderline significant in cells 
exposed to PFNA. This may support the previous reported effects of PFOS related to 
oestrogen signaling. A similar trend, but not significant, was found for PFNA.  
IPA gave insulin a central role in the top part of the network. Insulin has physiological 
effects on glucose, lipid and protein metabolism, and is shown to regulate cellular growth, 
differentiation and vascular function. Endocrine-disrupting chemicals may partly play a 
role in impairing the sensitivity of insulin. Non-esterified fatty acids, like PFCs, inhibit 
the carbohydrate metabolism and contribute to insulin resistance (Latini et al. 2009). A 
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recent study has shown a association between levels of PFCs in human serum and glucose 
homeostasis and indicators of metabolic disease (Lin et al. 2009). Endocrine disrupting 
chemicals have been reported to activate nuclear receptors and metabolic sensors, such as 
the PPARs. These have shown to be involved in the control of insulin sensitivity. PPARs 
are major regulators of lipid and glucose metabolism (Latini et al. 2009). Further, 
decreased levels of testosterone in human males have been associated with increased 
prevalence of obesity, insulin resistance and diabetes (Latini et al. 2009) which 
correspond to the findings in this study. 
In addition to insulin and beta-estradiol, IPA connected two more genes to the top part of 
the network; EWSR1 and NF-KB. EWSR1 is found to be a transcription factor involved 
in ewing sarcoma (Ishida et al. 1998). NF-KB has found to be a transcription factor 
involved in regulating genes involved in inflammation and immune functions, and have 
been found to be stimulated by oxidative stress (Ginn-Pease et al. 1998). 
The top part of the IPA network was defined to be involved in cancer, cell-to-cell 
signaling and interaction, and tissue development. This may indicate the carcinogenic 
effects of PFCs due to previous reports of the involvement of several of the regulated 
proteins in cancer development. Several studies have suggested that overexpression of 
HMGB is involved in development of cancer (Lange et al. 2009; Roesli et al. 2009). PDI 
has been reported to be one of the key elements in development of human lung cancer 
(Bührens et al. 2009) and TPI has been reported to play a role in pathology of human 
cancer (Bührens et al. 2009; Di Michele et al. 2010).  
The lower part of the network was defined by IPA to be involved in transcription and 
protein synthesis. The effect on transcription after exposure to PFCs has already been 
addressed when discussing the regulated proteins. 
 
5.6 Western blot 
The proteins quantified in the western blot analysis were chosen based on knowledge 
about proteins involved in steroidogenesis and cellular stress. StAR and CYP17 were 
measured to see whether there was regulation of the steroidogenic enzymes. Neither 
CYP17 nor StAR showed any differences in regulation after exposure to PFOS or PFNA. 
This corresponded to the results of identified spots after the proteomic analysis.  
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Bcl-2-like protein4 (BAX) is an apoptosis regulator in the bcl-2 family. It accelerates 
programmed cell death by binding to and antagonizing the apoptosis repressor BCL2 
(Alberts et al. 2004). BAX was quantified by western blot see whether the cells have an 
increased induction of apoptosis as a consequence of exposure. Cells exposed to PFOS 
had a decreased level of BAX. The decreased levels of BAX together with the reduced 
viability indicate that there is an increased level of apoptosis in these cells. Cell exposed 
to PFNA had not altered levels of BAX, which was a accordance with the viability test. 
Vimentin and HSP70 were measured due to the findings after proteomic analysis. HSP70 
was not regulated in the cells exposed to PFOS or the cells exposed to PFNA. This did 
not correspond to the regulation found after protein identification. A possible reason is 
that western blot measures the quantity of all the protein of interest, while identification 
done by proteomic analysis may have detected isomers. HSP70 may have been present in 
several spots in the 2D-gel, but only one of them was excised. Vimentin, however, was 
found up-regulated in the cells exposed to PFNA, but not regulated in cells exposed to 
PFOS. This correlated well with the LC-MS/MS. Vimentin was shown to be slightly up-
regulated in cells exposed to PFOS (fold change 1.7 and 1.2), but not as much as in the 
cells exposed to PFNA (fold change 2.0 and 2.6), after protein identification. 
 
5.7 Limitations to the current study 
5.7.1 Viability 
The decreased viability due to PFOS exposure was a great source of error in this study. 
The exposure doses used should have been lower to be able to have effects without the 
cytotoxicity, and to be able to detect NOAEL.  
 
5.7.2 Number of replicates 
In this study, 3 replicates were used for each exposure group. More replicates could have 
been conducted, but the experimental design caused limitations due to the huge amount of 
work and use of equipment.   
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5.7.3 TBA 
As already mentioned, TBA is a non-selective potassium channel blocker which may 
change the membrane potential, without changing the viability (Sohn et al. 2000). 
However, expression of HSP70 measured by western blot, gave increased levels in 
H295R cells exposed to TBA. This could imply that TBA had a stress-like effect on the 
cells. In addition four of the identified spots were down-regulated compared to the solvent 
control, including albumin in two different isomers, HMG1 and TPI. Albumin, in both the 
isomers, was up-regulated in cells exposed to PFOS as a TBA-salt, while it was down-
regulated in cells exposed to only TBA. HMG-1 is down-regulated in both cells exposed 
to PFOS as a TBA-salt, and TBA. TPI is down-regulated in cells exposed to TBA, while 
it is up-regulated in cells exposed to PFOS as a TBA-salt. These differences in up- and 
down-regulation suggest that TBA has an independent effect. A previous study indicated 
that PFOS may increase the permeability for other compounds (Hu et al. 2003), and it 
cannot be excluded that effects seen in cells exposed to PFOS could have been influenced 
by TBA. 
 
5.7.4 Limitations to proteomics 
Proteomic analysis gives a better understanding of disease processes and mechanisms of 
action than genomics. However, when interpreting results obtained in the present study, 
there were some limitations set by the method used. Firstly, the proteins are separated by 
both size and isoelectric pH and thus one protein could have been separated in several 
isomers. This means that one up-regulated or down-regulated spot did not necessarily 
represent the total amount of one protein, only regulation in one of the isomers. Secondly, 
one spot was not necessarily one protein, but might have consisted of several proteins. 
The software used in detecting the proteins uses a MOWSE score (Pappin et al. 1993), 
among other factors, to be able to say which of the proteins were most likely to be the 
most abundant protein in the spot. However smaller protein could have hidden in these 
spots. If a large spot was shown to be neither down- or up-regulated, there could still have 
been smaller proteins hiding which in fact were significantly regulated. Thirdly, the 
samples consisted of a large amount of proteins, while only a small number of proteins 
were identified due to limited resources. On the other hand, using Western blot, the total 
amount of the protein can be measured in a sample. Contrary to LC-MS, western blots 
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require knowledge on which proteins can be present in the sample based on the samples 
nature and the treatment.  
Another limitation to proteomic analysis is the random selection of which protein spots to 
identify. Out of the 180 significant spots in this study, 17 were excised and identified. 
These 17 spots were subjectively elected based on significance, fold change and 
evaluation of the quality of the spots. Ideally, all the spots should have been identified to 
get a better understanding of the mechanisms following exposure to PFOS and PFNA. 
However, because of limited resources, both time and money, this was not possible to do. 
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6. Conclusions 
Exposure to PFOS and PFNA caused both changes in protein expression and endocrine 
disrupting effects in the H295R in vitro cell model. The effects found in the H295R in 
vitro model, both the endocrine effects and alterations in proteins expression, cannot 
directly be transferred to in vivo systems. However, the alterations in hormones following 
exposure to PFCs have been reported earlier in both humans and wildlife. Hence, this 
study supports the PFCs effects on the hormone production and the endocrine effects of 
exposure to these compounds. The alterations in protein expression might also cause 
negative effects in in vivo mechanisms, but this should be futher studied.  
The changes in protein regulation caused by PFOS and PFNA included several classes of 
proteins, such as transcription factors, transportation proteins and stress related proteins. 
This suggested that exposure to these compounds affects several cellular processes, 
including protein synthesis, stress response and apoptosis. In addition, many of the 
proteins found are reported to be involved in carcinogenesis.  
The endocrine disrupting effects included changes in the hormone secretion; decreased 
levels of testosterone, progesterone and cortisol in both cells exposed to PFOS and 
PFNA. In addition oestradiol secretion increased in the cells. However, the increase was 
only statistically significant at the lowest concentration of PFOS. 
After quantification of proteins by western blot, enzymes involved in the steroidogenesis 
were not altered. This might suggest that the observed changes in hormone concentrations 
occure down-stream of these enzymes. Elevated BAX levels confirmed the reduced 
viability in cells exposed to PFOS. The western blot analysis of vimentin confirmed 
results from the proteomic analysis. Western blot done for HSP70 did not correlate with 
the proteomic findings. Still this may have a reasonable explanation.  
The H295R cell-line was found to be well suited for proteomic analysis, as the profile 
was clear with defined spots.  
The detected negative effects of PFOS and PFNA, especially the potential carcinogenic 
effects, should be investigated further, and taken in consideration in future utilization of 
these compounds. 
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7. Future perspectives 
All the interesting findings obtained from this study should be further investigated to be 
able to understand more details in mechanisms involved in exposure to PFCs. 
It would be interesting to excise and identify more of the significant proteins to obtain 
more knowledge about PFCs’ mode of action and interference in various cellular 
processes. In addition it would be interesting to expose the cells the same way as in this 
study (48h), but delay the isolation of proteins (24-48h). This may result in more 
representative proteins being regulated in the response to exposure.   
Both RNA and DNA were isolated from the exposed cells, and it would be interesting to 
analyze the gene expression using qPCR or microarrays, and/or analyze the DNA for 
epigenetic changes or DNA damage.  
The alterations of all the four hormones in the current study indicate the investigated 
compounds might affect hormonal axes in exposed individuals. It would be a future 
perspective to perform the same exposure in systems investigating the other parts of the 
HPA-axis, or in living animals with intact hormonal axes. 
Previous studies have reported of oxidative stress caused by PFCs in which was 
confirmed in this study by alterations in stress related proteins. Further studies could be 
done in H295R cells to investigate the mechanisms behind oxidative stress caused by 
PFCs. 
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Appendix 1: Equipments 
Equipment/kits   
1,5 ml eppendorf tubes VWR International AS, Oslo, Norway 
7 cm ImmobilineTM DryStrips pH 3-10 NL 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
75 cm2 flasks (T75) BD Falcon, New Jersey, USA 
96-well plates VWR International AS, Oslo, Norway 
Allprep® DNA/RNA/Protein Mini Kit Qiagen, Crawley, UK 
Blotting cassettes MIDSCI, Saint Louis, Missouri, USA 
Blotting filter papir MIDSCI, Saint Louis, Missouri, USA 
Bürker haematocytometer Superior, Marienfeld, Germany 
Cell strainer  BD Biosciences, NJ, USA 
Cell-line H295R  
American Type Culture Collection (ATCC # 
CRL-2128, ATCC, Manassas, VA, USA) 
Coat-A-Count Cortisol kit  
Siemens Medical Solutions Diagnostics, Los 
Angeles, CA, USA 
Coat-A-Count Estradiol kit  
Siemens Medical Solutions Diagnostics, Los 
Angeles, CA, USA 
Coat-A-Count Total Testosterone kit  
Siemens Medical Solutions Diagnostics, Los 
Angeles, CA, USA 
Dry strip alligner 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
Dry strip cover fluid 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
Dulbecco’s Modified Eagles Medium and 
Ham’s F-12 Nutrient mixture (1:1) 
Sigma D-2906; Sigma-Aldrich, Inc, St Louis, 
MO, USA 
Falcon 10 ml BD Falcon, New Jersey, USA 
Falcon 50 ml BD Falcon, New Jersey, USA 
Foam pads MIDSCI, Saint Louis, Missouri, USA 
Immobiline IPG reswelling cassette 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
Immobilon-FL membrane  Milipore (UK) Ltd, Watford, UK 
Invitrogen antioxidant Invitrogen, Carlsbad, CA, USA 
LiCor 2 colour marker LI-COR Biosciences, Lincoln, NE, USA 
Microcuvettes VWR International AS, Oslo, Norway 
Mini Protean 3 gel system 
Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK 
NuPage® Novex Antioxidant Invitrogen, Carlsbad, CA, USA 
NuPage® Novex Midi Bis-Tris Gel  Invitrogen, Carlsbad, CA, USA 
NuPage® Novex Reducing Agent Invitrogen, Carlsbad, CA, USA 
Odyssey® Two-Color Protein Molecular Weight 
Marker  LI-COR Biosciences, Lincoln, NE, USA 
Owl Bandit Transfer Tank MIDSCI, Saint Louis, Missouri, USA 
Pipette aid XP Drummond Scientific co., PA, USA 
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Pipette PS Steril 1 ml VWR International AS, Oslo, Norway 
Pipette PS Steril 10 ml VWR International AS, Oslo, Norway 
Pipette PS Steril 2 ml VWR International AS, Oslo, Norway 
Pipette PS Steril 25 ml VWR International AS, Oslo, Norway 
Pipette PS Steril 5 ml VWR International AS, Oslo, Norway 
Pipette tips 1000p (filtered) Fisher Scientific, Pittsburgh, PA, USA 
Pipette tips 10p (filtered) Fisher Scientific, Pittsburgh, PA, USA 
Pipette tips 200p (filtered) Fisher Scientific, Pittsburgh, PA, USA 
Pipette tips 20p (filtered) Fisher Scientific, Pittsburgh, PA, USA 
Qia Shredder  Qiagen, Crawley, UK 
RC DC Protein Assay  
Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK 
ReadyPrepTM 2-D Cleanup Kit  
Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK 
SeeBlue Plus 2 Pre-Stained Standard Invitrogen, Carlsbad, CA, USA 
Spectria Progesterone RIA kit  Orion Diagnostica, Espoo, Finland 
Xcell SureLock Electrophoresis Unit Invitrogen, Carlsbad, CA, USA 
ZOOM® Gels  Invitrogen, Carlsbad, CA, USA 
 
Chemicals   
0.25 % trypsin/0.53 nM EDTA  Gibco, Invitrogen, Paisley, USA 
2-Mercaptoethanol Sigma-Aldrich, Inc, Saint Louis, MO, USA 
3-((3-Cholamidopropyl) dimethylammonio)-1-
propanesulfonate (CHAPS) Fisher Scientific, Pittsburgh, PA, USA 
Acetonitrile  
Rathburn Chemicals Ltd, Walkerburn, 
Scotland 
Acrylamid Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Alamar Blue Invitrogen, Carlsbad, CA, USA 
Ammounium persulphate Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Ammounium sulphate Sigma-Aldrich, Inc, Saint Louis, MO, USA 
BD Nu-Serum BD Bioscience, San Jose, CA, USA 
Bovine serum albumin (BSA)  
A7906, Sigma-Aldrich, Inc, Saint Louis, 
MO, USA 
Bromophenol Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Coomassie Blue G250  Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Dithiothreitol (DTT) Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Dithiothreitol (DTT) Fisher Scientific, Pittsburgh, PA, USA 
Ethanol Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Formic acid  
Mallinckrodt Baker, Inc., Phillipsburg, NJ, 
USA 
Glycerol Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Glycine Sigma-Aldrich, Inc, Saint Louis, MO, USA 
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Iodoacetamide Sigma-Aldrich, Inc, Saint Louis, MO, USA 
ITS+ Premix BD Bioscience, San Jose, CA, USA 
Methanol Sigma-Aldrich, Inc, Saint Louis, MO, USA 
N, N, N', N'-tetramethylenethylenediamine 
(TEMED) Sigma-Aldrich, Inc, Saint Louis, MO, USA 
N-Methylene Bis-acrylamid Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Perfluorononanoic acid Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Phosphatase Inhibitor Cocktail 1   Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Phosphate Buffered Saline (PBS) - 
ICN92810305 Fisher Scientific, Pittsburgh, PA, USA 
Phosphoric acid Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Protease Inhibitor Cocktail Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Sodium dodecyl sulphate (SDS) Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Tetrabutylammonium chloride Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Tetrabutylammonium 
heptadecafluorooctanesulfonate  Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Thiourea  
Fluka, Sigma-Aldrich, Sain Louis, Missouri, 
USA 
Trizma-base Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Trypsin Promega UK, Southampton, UK 
Tween Sigma-Aldrich, Inc, Saint Louis, MO, USA 
Urea Fisher Scientific, Pittsburgh, PA, USA 
 
Commercial buffers   
IPG equilibrating buffer  
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
IPG Reswell buffer 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
MOPS 20x concentrate buffer Invitrogen, Carlsbad, CA, USA 
NuPage® 20x Transfer buffer Invitrogen, Carlsbad, CA, USA 
NuPage® Novex LDS Sample Buffer (4x) Invitrogen, Carlsbad, CA, USA 
NuPage® Novex MOPS running buffer Invitrogen, Carlsbad, CA, USA 
Odyssey Blocking Buffer  LI-COR Biosciences, Lincoln, NE, USA 
 
Instruments   
Centrifuge, GS-6R Centrifuge 
Beckman Coulter, Brea, CA 92822-8000 
USA 
CO2 incubator Hera Cell 150, Heraeus, Hanau, Germany 
EasyBreeze Gel Drier Hoefer, Inc., Holliston, MA, USA 
EPS 3000 XL Power Supply Pharmacia Biotech 
Flow-Cabinet, Kojair® Tampere, Finland 
Grant QBT2 Heatblock Grant Instruments (Cambridge) Ltd., Herts, 
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England 
HCTultra PTM Discovery System  Bruker Daltonics Ltd., Coventry, UK 
ImageScanner TM III  GE Healthcare, Uppsala, Sweden 
Investigator ProGest robotic workstation  Genomic Solutions Ltd., Huntingdon, UK 
Invitrogen Power Supply Invitrogen, Carlsbad, CA, USA 
LAF bench ScanLaf AS, Lynge, Denmark 
Microscope - Nikon TMS Interfoto Instrument AS, Høvik, Norway 
Multiphor II  Electrophoresis System 
GE Healthcare Bio-Sciences AB, Uppsala, 
Sweden 
NanoDrop Thermo-Scientific, Waltham, MA, USA 
Odyssey infrared fluorescence imager  LI-COR UK Ltd. UK 
Phoretic-1D Advanced software  Nonlinear Dynamics Ltd, Newcastle, UK 
Power Pac 3000 Power Supply 
Bio-Rad Laboratories Ltd, Hemel 
Hempstead, UK 
SC110 Speedvac Savant Instruments, Holbrook, NY, USA 
UltiMate 3000 LC System  Dionex (UK) Ltd., Camberley, Surrey, UK 
UV/VIS spectrophotometer  Lambda 1, Perkin-Elmer, Shelton, CT, USA 
Vacusafe comfort 
© INTEGRA Biosciences 2008, Chur, 
Switzerland 
Victor 3™ 1420 Multilabel counter Perkin Elmer, MA, USA 
Vortex LR Labinco L24 Labinco, Breda, Netherlands 
Wallac 1470 Wizard™ automatic gamma 
counter Perkin Elmer, MA, USA 
Waterbath, Lauda Ecoline 019 Lauda-Königshofen, Germany 
 
Softwares   
Data Analysis software  Bruker Daltonics Ltd., Coventry, UK 
Ingenuity Pathway Analysis Ingenuity Systems Inc, CA, USA 
JMP 8 software  SAS Institute Inc, Cary, NC, USA 
LabScan software GE Healthcare, Uppsala, Sweden 
Phoretic-1D Advanced software  Nonlinear Dynamics Ltd, Newcastle, UK 
Progenesis Samespots v 3.3 Nonlinear Dynamics Ltd, Newcastle, UK 
R 2.10.1 The R Foundation for Statistical Computing  
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Appendix 2: Buffers used in protein isolation 
 
Modified Reswell Buffer 
Urea     2.01 g 
Thiourea    0.7 g 
CHAPS    0.2 g 
DTT     0.015 g 
MilliQ water    3 mL 
Dissolve all the chemicals in water. Mix well, and make sure all the chemicals dissolves. 
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Appendix 3: Standards for protein quantification 
 
Standards for Protein Assay: 
Stock standard = 14,4 mg/ml 
Standard 1 = 1.5 mg/ml:  70µl stock + 602µl dH2O 
Standard 2 = 1.0 mg/ml:  200µl 1.5 mg/ml std + 100µl dH2O 
Standard 3 = 0.75 mg/ml: 100µl 1.5 mg/ml std + 100µl dH2O 
Standard 4 = 0.5 mg/ml: 100µl 1.5 mg/ml std + 200µl dH2O 
Standard 5 = 0.2 mg/ml: 20µl 1.5 mg/ml std + 130µl dH2O 
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Appendix 4: Standard curve and calculation after RC DC 
Protein assay 
Prøve Abs Average  Stdev % var CV Conc (µg/µl) V (µl) Ammount (µg)
Standard 1 0,414 0,397    0,025 9 %      6,242 1,5     
Standard 1 0,379         1,5     
Standard 2 0,279 0,280    0,001 1 %      0,505 1     
Standard 2 0,281         1     
Standard 3 0,194 0,210    0,023 15 %    10,775 0,75     
Standard 3 0,226         0,75     
Standard 4 0,145 0,143    0,003 3 %      1,978 0,5     
Standard 4 0,141         0,5     
Standard 5 0,063 0,063    0,001 2 %      1,131 0,2     
Standard 5 0,062         0,2     
Lav kontroll 0,098 0,105    0,010 13 %      9,428 0,35     
Lav kontroll 0,112               
Høy kontroll 0,393 0,378    0,021 8 %      5,612 1,41     
Høy kontroll 0,363               
0,1 % DMSO 020409 0,226 0,214    0,017 11 %      7,930 15,46 195 3014,87
0,1 % DMSO 020409 0,202               
150 µM TBA 020409 0,234 0,231    0,004 3 %      1,837 16,78 195 3271,65
150 µM TBA 020409 0,228               
175 µM TBA 020409 0,211 0,213    0,002 1 %      0,998 15,34 195 2992,22
175 µM TBA 020409 0,214               
200 µM TBA 020409 0,230 0,227    0,004 3 %      1,869 16,47 195 3211,23
200 µM TBA 020409 0,224               
150 µM PFOS 020409 0,135 0,143    0,011 11 %      7,443 9,92 195 1934,90
150 µM PFOS 020409 0,150               
175 µM PFOS 020409 0,028 0,034    0,008 33 %    23,218 1,48 195 288,50
175 µM PFOS 020409 0,039               
200 µM PFOS 020409 0,030 0,031    0,001 3 %      2,318 1,25 195 243,18
200 µM PFOS 020409 0,031               
175 µM PFNA 020409 0,153 0,144    0,013 13 %      8,839 10,04 195 1957,55
175 µM PFNA 020409 0,135               
200 µM PFNA 020409 0,138 0,144    0,008 8 %      5,420 10,00 195 1950,00
200 µM PFNA 020409 0,149               
0,1 % DMSO 030409 0,262 0,253    0,013 7 %      5,031 18,48 195 3603,95
0,1 % DMSO 030409 0,244               
150 µM PFNA 030409 0,231 0,227    0,006 4 %      2,492 16,47 195 3211,23
150 µM PFNA 030409 0,223               
175 µM PFNA 030409 0,301 0,287    0,021 10 %      7,157 21,08 195 4109,95
175 µM PFNA 030409 0,272               
200 µM PFNA 030409 0,229 0,225    0,006 4 %      2,835 16,27 195 3173,47
200 µM PFNA 030409 0,220               
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The standard curve is made by plotting the absorbance of the standards against the known 
concentration. The formula is calculated, and used to calculate the protein concentrations 
in the samples.  
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Appendix 5: Buffers used in 1D-gels and 2D-gels 
 
Phosphate Buffered saline (PBS): 
Sodium chloride   12 g 
Potassium chloride    0.3 g 
DiSodium phosphate   1.73 g 
Sodium dihydrogen phosphate  0.3 g 
Adjust to a final volume of 1200 mL with MilliQ water. pH should be ca. 7.4 without adjustment.  
 
IPG Reswell Buffer 
Urea     2.01 g 
Thiourea    0.7 g 
CHAPS    0.2 g 
DTT     0.015 g 
MilliQ water    3 mL 
IPG Buffer    50 µL 
Add sufficient bromophenol to give a blue color to the solution. 
 
30 % Acrylamid solution 
Acrylamid     150 g 
N-methylene Bis-acrylamid  4.0 g 
Adjust to final volume of 500 mL with MilliQ water. 
 
2M Tris-HCL, pH 8.8 
Trizma-base    121.1 g 
Dissolve in approximately 400 mL water, and adjust pH 8.8 with 6M HCL. Adjust to a final 
volume of 500 mL with MilliQ water. 
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0.5 M Tris-HCL, pH 6.8 
Trizma-base    15.1 g 
Dissolve in approximately 200 mL MilliQ water, and adjust pH 6.8 with 6M HCL. Adjust to a 
final volume of 250 mL with MilliQ water. 
 
10 % Ammonium persulphate 
Ammonium persulphate   1.5 g 
MilliQ water    15 mL 
Prepare fresh immediately before use 
 
10 % Sodium Dodecyl Sulphate (SDS) 
SDS      25 g 
Adjust final volume of 250 mL with MilliQ water. 
 
 
25 % Sodium Dodecyl Sulphate (SDS) 
SDS     25 g 
Adjust to a final volume of 100 mL with MilliQ water. 
 
N, N, N’, N’-tetramethylenthylenediamine (TEMED) 
Use undiluted as obtained from the supplier. 
 
3x Dissociation Buffer 
0.5 M Tris- HCL, pH 6.8  2.0 mL 
25 % SDS    1.7 mL 
2-Mercaptoethanol   1.3 mL 
Glycerol    2.0 mL 
Add bromophenol blue to give a blue color to act as a tracking dye during electrophoresis. 
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Electrophoresis Running Buffer 
Glycine     6.0 g 
Trizma base    9.5 g 
SDS     1.5 g 
Adjust to a final volume of 1000 mL with MilliQ water. 
 
Resolving gel composition 
Stock solution Resolving gel concentration – 10 % 
30 % Acrylamid (mL) 6.67 
2M Tris-HCL pH 8.8 (mL) 3.75 
10 % SDS (mL) 0.2 
MilliQ water (mL) 9.38 
  
Catalysts  
TEMED (µL) 10 
10 % (w/v) Ammonium persulphate (µL) 100 
 
 
Stacking gel composition 
Stock solution 3.6 % stacking gel 
30 % Acrylamid (mL) 0.6 
2M Tris-HCL pH 8.8 (mL) 1.2 
10 % SDS (mL) 0.05 
MilliQ water (mL) 3.14 
  
Catalysts  
TEMED (µL) 5 
10 % (w/v) Ammonium persulphate (µL) 50 
 
IPG Equilibration Buffer 
0.5 M Tris-HCL, pH 6.8  80 mL 
Urea     288 g 
Glycerol    240 mL 
10 % SDS    160 mL 
Adjust final volume to 800 mL with MilliQ water. 
 
 
 
139 
    
Gel fixing solution 
Ethanol    500 mL 
Phosphoric acid  20 mL 
Adjust to a final volume of 100 mL with MilliQ water. 
 
Colloidal Coomassie Brilliant Blue (CBB) Equilibration Buffer 
Ammonium sulphate    34 g 
Methanol    68 mL 
Phosphoric acid  4 mL 
Dissolve the ammonium sulphate in ~100 mL of water, and once it is in solution adjust to a final 
volume of 128 mL. Add the methanol and a white precipitate will form which dissolves after the 
addition of the phosphoric acid. 
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Appendix 6: Buffers used in LC-MS 
 
Ammonium Bicarbonate (AMBIC) 100mM Solution 
Dissolve 0.79 g Ammonium Bicarbonate in 100mL of UHQ water and filter (7.9mg/mL) 
 
Dithiothreitol (DDT) 10mM solution 
Dissolve 30mg DTT in 20mL of 50mM AMBIC and filter (1.5mg/mL) 
 
Iodoacetamide 55mM solution 
Dissolve 200mg Iodoacetamide in 20mL 50mM AMBIC and filter (10mg/mL) 
 
Trypsin preparation 
To a 20µg vial of porcine Trypsine add 1mL of UHQ water and mix thoroughly. Add to this 1µL 
of conc. Formic acid, which will help the longer-term storage of the trypsin solution as it’s 
unlikely that whole vial will be required. 
Dilute an aliquote of trypsin 10 times in 100mM AMBIC to give a working solution of 2ng per 
µL. 
 
10 % Formic acid in water  
Dissolve 10mL of conc. Formic acid in 90mL UHQ water. 
 
Eluent A – 0.05 % Formic acid in water with 3 % acetonitrile 
To 970mL of UHQ water add 30mL acetonitrile and 500µL formic acid 
 
Eluent B – 80 % Acetonitrile in 0.04 % formic acid 
To 800mL acetonitrile add 200mL UHQ water and 400µL formaic acid 
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Appendix 7: Buffers used in western blot 
 
1x SDS Running buffer for outer chamber 
50 mL of Invitrogen 20x NuPAGE MOPS Running Buffer 
Fill up with dH2O to a final volume of 1L 
 
1x running buffer for inner chamber 
200 mL of 1x SDS Running buffer for outer chamber 
500µL of Invitrogen NuPAGE Antioxidant 
 
1x transfer buffer 
200 mL of 20x Invitrogen NuPAGE transfer buffer 
200 mL of 100 % methanol 
2.0 g of SDS 
2.0 mL of Invitrogen NuPAGEAntioxidant 
1600 mL dH2O 
 
PBS 
Use 5 x ICN PBS tablets (cat no. 2810305) dissolved in 500mL dH2O 
 
PBST 
Use 500mL of PBS from above and add 1mL of Tween (Sigma P-2287) 
 
Odyssey Blocking Buffer cat no. 927-40000 
 
 
